KEVIN THOMAS McVARY
June 2011
CURRICULUM VITAE
1. PERSONAL INFORMATION
Name: Kevin T. McVary, M.D., F.A.C.S.
Professor of Urology
Office: Northwestern University Feinberg School of Medicine
Department of Urology
Tarry Building, Room 16-749
303 East Chicago Avenue
Chicago, IL. 60611-3008
(312) 908-8145
Northwestern Medical Faculty Foundation
Galter Building, Room 20-150
675 N. St. Clair St.
Chicago, IL 60611
Northwestern Memorial Hospital
201 E. Huron St.
Chicago, IL 60611
Fax: (312) 908-7275
E-mail: k-mcvary@northwestern.edu
Citizenship: USA
Place of Birth: Springfield, IL
2. EDUCATION
1979 Northwestern University, Evanston, IL, BA, Biology
1983 Northwestern University Medical School, Chicago, IL., MD, Medicine
3. GRADUATE MEDICAL EDUCATION
1983 - 1984 Northwestern Memorial Hospital, Internship, Chicago, IL General Surgery
1984 - 1985 Northwestern Memorial Hospital, Chicago, IL, Junior Resident, General Surgery
1985 - 1986 Northwestern Memorial Hospital, Chicago, IL, Junior Resident, Urology
1986 - 1987 Northwestern Memorial Hospital, Chicago, IL, Senior Resident, Urology
1988 - 1989 Northwestern Memorial Hospital, Chicago, IL, Chief, Resident, Urology
4. POSTDOCTORAL RESEARCH TRAINING
1987 - 1988 Northwestern University Medical School, Chicago, IL, Riba Urology Research Fellowship, (Preceptor: Dr. Chung Lee)
5. BOARD CERTIFICATION AND MEDICAL LICENSURE
1983 Licensed Physician and Surgeon, State of Illinois
1984 National Board of Medical Examiners
1989 American Board of Urology Exam, Part I
1991 American Board of Urology, Exam, Part II; recertified – 2000, 2010
2000 Licensed Physician and Surgeon, Honduras, C.A.
6. MILITARY SERVICE: NA
7. FACULTY APPOINTMENTS
1988 - 1989 Instructor, Northwestern University Medical School, Chicago, IL.,
Department of Urology
1989 - 1996 Assistant Professor, Northwestern University Medical School, Chicago, IL., Department of Urology
1996 - 2005 Associate Professor, Northwestern University Medical School, Chicago, IL., Department of Urology
2005 - present Professor, Northwestern University Feinberg School of Medicine, Chicago, IL,
Department of Urology
8. HOSPITAL APPOINTMENTS
1989 - present Director, Sexual Dysfunction, Division of Urology, Veterans Administration Lakeside Medical Center, Chicago, IL.
1989 - 2003 Chief, Section of Urology, Veterans Administration Crown Point Ambulatory Care Center, Chicago, IL.
1989 - present Attending Staff Urologist, Northwestern Memorial Hospital, Chicago, IL.
1989 - 2007 Attending Surgeon, Veterans Administration Lakeside Medical Center,
Chicago, IL.
1990 - present Consultant, Rehabilitation Institute of Chicago, Chicago, IL.
1995 – 2003 Chief, Section of Urology, Veterans Administration Lakeside Medical Center, Chicago, IL.
9. ADMINISTRATIVE APPOINTMENTS
Teaching:
1992 - present Faculty Member, Medical Scientist Training Program, Northwestern University Medical School, Chicago, IL.
1994 - present Director, Continuing Medical Education, Clinical Update Program, Northwestern University Medical School, Chicago, IL.
Institutional Administrative Posts:
1989 - present Director, Sexual Dysfunction, Northwestern University Medical School/Northwestern Memorial Hospital, Chicago, IL.
1992 - 1995 Faculty Planning Committee, Northwestern Medical Faculty Foundation, Chicago, IL.
1992 - 1996 Facilities Planning Committee, Northwestern University Medical School, Chicago, IL.
1992 - present Associate Director, Clinical Laboratory, Department of Urology, Northwestern University Medical School, Chicago, IL.
1992 - 1999 Chairman, Residency Selection Committee, Department of Urology, Northwestern University Medical School, Chicago, IL.
1993 - present Medical Information System, Northwestern Medical Faculty Foundation, Chicago, IL.
1993 - present Research and Development Committee, Veterans Administration Lakeside Hospital, Chicago, IL.
1993 - present Faculty Member, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL.
1996 - present Medical Student Research Committee, Northwestern University Medical School, Chicago, IL.
2000 - present Facilities Planning Committee, Northwestern Medical Faculty Foundation, Chicago, IL
10. COMMITTEE SERVICE
Medical School:
1992 - present Scientific Advisory Committee, General Clinical Research Center
1993 - present Medical Information System Committee
1998 - present Fourth Year Medical Student Curriculum Committee
2001- present Clinical Research and Training Committee
University:
1989 - present Research Committee, Department of Urology, Northwestern University Medical School
2003 - present Member, Program Review Council, Northwestern University Feinberg School of Medicine
2003 - 2004 Subcommittee Chair for the Program Review Council for the Department of Radiology, Northwestern University Feinberg School of Medicine
2004 – 2006 Subcommittee Chair for the Program Review Council for the Department of Ophthalmology, Northwestern University Feinberg School of Medicine
2006 - present Subcommittee Chair for the Program Review Council for the Department of Materials Research Center, Northwestern University
2006 - present Mentoring the Mentors Program, Northwestern University Feinberg School of Medicine
Hospital:
1990 - present Physician Standards Ethics Ad Hoc Committee, Northwestern Memorial Hospital
1992 - present Patient Care and Standards Committee, Northwestern Memorial Hospital
1993 - present Research and Development Committee, Veterans Administration Lakeside Hospital
1995 - present Continuing Medical Education (CME) Committee, Northwestern Memorial Hospital
2002 - present Chairs and Chiefs Committee for the O.R., Northwestern Memorial Hospital
Northwestern Medical Faculty Foundation:
1992 - 2003 Clinical Practice Director, Northwestern Medical Faculty Foundation, Department of Urology
1995 - present Managed Care Committee
11. AWARDS, HONORS, DISTINCTIONS
1977 Phi Eta Sigma, Northwestern University
1979 Marcy Scholar, Northwestern University
1979 Phi Beta Kappa, Northwestern University
1988 First place for Resident Research, Traveling Fellowship Award of the North Central Section of the American Urological Association, presented in November, 1988, Orlando, Florida, for research on fetal urinary obstruction
1988 Second prize for resident basic science research at 1988 meeting of the American Academy of Pediatrics, Urology Section, presented in San Francisco, California
1989 First place for laboratory research in American Urological Association Prize Essay Contest for “Urinary obstruction reduces glomerulogenesis in the developing kidney: A model in the rabbit”
1994 Visiting Scientist, University of Hong Kong, Hong Kong
1999 First prize essay at Society for the Study of Impotence, Boston, MA. Gonzalez CM, Bervig T, Podlasek C, McKenna KE, and McVary KT: Sildenafil Causes a Dose and Time Dependent Downregulation of PDE Type 6 Expression in the
Rat Retina.
2000 Finalist for Burroughs-Wellcome Translational Research Award
2001 First prize essay at Sexual Medicine Society of North America, Inc., December 2001 Podlasek CA, Gonzalez CM, Zelner DJ, Jiang HB, McKenna KE, and McVary KT: Analysis of Potential NOS Isoform Changes in Post Radical Prostatectomy Model of Erectile Dysfunction.
2003 Visiting Professor, Boston University School of Medicine, Department of Urology, Boston, MA
2003 Visiting Professor, University of Texas Houston Medical School, Houston, TX
2003-2009 Best Doctors in America
2004 Visiting Professor, University of Minnesota, Department of Urology, Minneapolis, MN
2004 Visiting Professor, University of Washington, Department of Urology, Seattle, WA
2004 AcademicsKeys Who’s Who in Medical Sciences Education (WWMSE)
2004 Prize Essay Contest, International Society for Sexual and Impotence Research
2005 Alumni Member, Northwestern University’s Chapter (Gamma) of Alpha Omega Alpha, Honor Medical Society
2005 Visiting Professor, University of Cincinnati, Department of Urology, Cincinnati, OH
2006 Best Reviewer in 2005 Award presented by the Editors of The Journal of Urology
2006 Visiting Professor, University of Cincinnati, Division of Urology, Cincinnati, OH
2006 Recipient Award for Excellence at Jackson Hole Urology Conference
2008 Visiting Professor, University of Oregon, Department of Urology, Portland, OR
2008 Who’s Who in America
2008 Visiting Professor, Ohio State University, Department of Urology, Columbus, OH
2009 Visiting Professor, Cornell University, Department of Urology, New York, NY
2009 Best Reviewer, The Journal of Urology
2010 Visiting Professor, Montefiore Medical Center, Department of Urology, New York, NY
2010 Visiting Professor,Wake-Forest University, Department of Urology, Winston-Salem, NC
2011 Visiting Professor, Umea Medical School, Sweden
2011 Visiting Professor, Uppsala Universitet : Department of Urology
12. PROFESSIONAL SOCIETY MEMBERSHIPS
Memberships and Leadership Positions:
1988 - present American Urological Association, Diplomate
1988 - present American College of Surgeons, Fellow
1989 - present Chicago Urologic Society
1989 - present North Central Section of AUA, Active Member
Illinois State Urologic Society
1990 - present American Medical Association
1990 - present International Society of Impotence Research
1990 - present Center for Reproductive Science, Northwestern University
1992 - present American Society of Andrology
1993 - present Society for Basic Urology Research (SBUR)
1993 - present American Association of Clinical Urologists, Inc.
1994 - present Society for the Study of Impotence/Sexual Medicine Society
1994 - present United States Section of the Societe Internationale d’Urologie
1994 - present Society of University Urologists
1994 - present Societe Internationale d’Urologie
1995 - present Urologic Investigative Forum
2001- 2002 Sexual Medicine Society Health Policy Smoking and Erectile Dysfunction
Committee - Chairman
2001 - 2002 Sexual Medicine Society Health Policy Committee
2001- present Sexual Medicine Society Nominating Committee
2002 - 2009 American Urological Association Program Committee
2002- 2006 Executive Committee Member of the Chicago Urologic Society
2004 – present Member, Editorial Board, Investigative Urology Section
2006 - present Chair, BPH Guidelines Panel, American Urological Association
2006 – 2010 Chair, BPH Clinical Guidelines Panel, American Urological Association
2006 – 2010 Member, American Urological Association Public Media Committee
2007 - 2008 Secretary, Chicago Urologic Society
2008 - 2009 Vice-President, Chicago Urologic Society
2009 - 2010 President, Chicago Urologic Society
2008 - present Member, American Association of Genitourinary Surgeons
2009 - present Vice-Chair, Public Media Committee, American Urological Association
2009- present Member, Male Health Ad Hoc Committee, American Urological Association
13. PROFESSIONAL AND SCIENTIFIC SERVICE
Leadership Positions:
1995 - present Steering Committee: NIH Sponsored Medical Therapy for BPH, NIDDK
1995 - present Chairman, Patient Recruitment Committee: NIH Sponsored Medical Therapy for BPH, NIDDK
1995 - 1996 PSA + Prostate Biopsy Committee: NIH Sponsored Medical Therapy for BPH, NIDDK
1995 - 1997 Chairman of the Form Committee; NIH Sponsored Medical Therapy for BPH, NIDDK
2001 - present Chairman, NIDDK Data Committee: NIH Sponsored MIST Trial
2002 - present Chairman, NIDDK Outcomes and Data Assessment: NIH Sponsored CAMUS Trial
2003 - present Member, NIDDK Urologic Complications of Diabetes Research Group, NIH
2003 - present Member, NIH Planning Committee for a Clinical Research Career in Urology
2003 - present Chairman, CAMUS Patient Recruitment and Forms Committee:
NIH Sponsored Trial
2004 Chairman, Patient Adherence and Recruitment Committee, NIH Sponsored MIST Trial
2006 Reviewer for Urological/Renal Development/Urogynecological Applications in a Special Emphasis Panel (SEP)
2006 Member, NIH/NIDDK Strategic Planning Committee for Prostate Research/Men’s Health
2006 AUA/ABU Control Guidelines Chair – BPH
2009 – present Data and Safety Monitoring Board, NIDDK Lifestyle Intervention to Treat Erectile Dysfunction
Editorial Service/Consultant:
Consultant American Journal of Kidney Diseases
Consultant American Journal of Obstetrics and Gynecology
Consultant Journal of Andrology
Consultant Journal of Urology
Consultant International Journal of Impotence Research (IJIR)
Consultant Journal of Investigative Urology
Consultant Doody’s Journal - Health Sciences Book Review
Consultant Urology
Consultant Journal of Laparoendoscopic Surgery
Co-Editor (1996-1999) Society for Study of Impotence Newsletter
Book Reviewer Journal of Urology
BPH Section Editor Current Urology Reports
Editor Prostate Current Reports
Editor Journal of Medicine
Editor Contemporary Treatment of Erectile Dysfunction: A Clinical Guide
Reviewer (2007- ) Practical Reviews in Urology, Oakstone Medical Publishing, Birmingham, AL
Editor Editorial board of Patient Related Outcome Measures
Board Member Editorial board of Asian Journal of Andrology
Review Bodies:
1990 - present Grant Reviewer, NIDDK
1994 - present Grant Reviewer, Merit Review Grant, Department of Veterans Affairs
1996 - present Department of Veterans Affairs - Pharmacy Benefits Management Strategic Health Group
1997 - present Grant/Site Visit Review Team NIDDK
1998 - present Exam Committee for American Board of Urology
2001 - National Medicare Guideline Writing Group for Thermotherapy (BPH)
2001 - Peer Reviewer for the Surgeon General’s Report on Active Smoking and Health
National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention
2001 - Peer Review Panelist for the Department of Defense, U.S. Army Medical Research, and Material Command Congressionally Directed Medical Research Program
2001 - 2003 Permanent Member, NIDDK Urologic Special Emphasis Panel
2003 Chairman, NIDDK-Urologic Complications of Diabetes-Basic Science Section-Erectile Dysfunction
2003 - 2004 Chairman, NIDDK-Urology Special Emphasis Panel
2004 - Chairman, NIDDK Urologic and Kidney Development and Genitourinary Diseases Study Section
2004 - Grant Reviewer, BPH Technology Assessment from the Study Section Center for Outcomes and Effective Aging and Healthcare and Quality.
2004 - Peer Reviewer for the Surgeon General’s Report on The Health Consequences of Smoking. US Department of Health and Human Services under the general direction of the Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health
Professional Public Service (Local):
1992 - present Speaker, Sexual Dysfunction in Prostate Cancer, US TOO (Prostate Cancer
Survival Support Group)
1992 - present Speaker, Patient Education Seminar, Northwestern Memorial Hospital - Variety of Topics Including BPH, Prostate Cancer, Impotence and Testicular Cancer
1993 - present Speaker, Urinary Incontinence in Prostate Cancer, US TOO (Prostate Cancer
Survival Support Group)
Professional Public Service (National):
2000 - present Consultant, Abbott
2001 - present Consultant, Eli Lilly Co.
2001 - present Consultant, Caremark
2001 - 2005 Consultant, Merck
2002 - present Consultant, Sanofi Aventis
2002 - present Consultant, GlaxoSmithKline
2005 - present Consultant, Medtronic
2002 - present Consultant, Urologix
Public Service (International):
1999 - present Committee Member for the World Health Organization Sponsored Consultation on Erectile Dysfunction
14. TEACHING
SUMMARY OF TEACHING EXPERIENCE:
Scheduled Assignments
Lectures
Pathophysiology, Prostate cancer 1990 – 1994 (Lecturer)
50-minute lecture to entire Sophomore class discussing (a) biology of prostate cancer, (b) patterns and organs predilection of metastasis, (c) treatment for prostate cancer, and (d) surgical and medical management of prostate cancer.
Scientific Basis of Disease: Prostate diseases 1995 – present (Lecturer)
50 minute lecture to entire sophomore class discussing (a) natural history of BPH, (b) biology of prostate cancer, (c) patterns of prostate cancer metastasis, (d) treatment of prostate cancer, and (e) surgical management and medical management of BPH.
Scientific Basis of Medicine: Renal Unit 2009 – present (Unit Chairman)
Coordinate lectures of approximately 15 faculty from Urology and pathology to the entire sophomore class discussing GU malignancies and benign diseases. This includes lectures, discussion groups, test construction and post test interviews with student panel.
Pathophysiology, Uroradiology: Uropathology 1990 – present (Conference Leader)
50 minute session/year to Sophomore students (15-20 per group) consisting of (a) 25 minute didactic on the differential diagnosis of hematuria and (b) 25 minutes of case presentations (including diagnostic x-rays) depicting common disease processes.
Introduction to Clinical Medicine: 1993 – present (Lecturer)
60 minute session/5 x year to new junior students consisting of (a) 15 minute didactic on the anatomy, proper catheterization technique and uropathology of male and female urethra and (b) 45 minute “hands on” session practicing urethral catheterization on male and female mannequins.
MSC Course: 2003 – present (Lecturer)
50 minute session/6 x year to new junior medical students on the topic of erectile dysfunction.
Laboratory Sessions
My basic research activities take place in the Tarry Building where I direct a 1200 square foot, fully equipped RT-PCR facility neurourology laboratory, and in vivo animal experimental laboratory. My laboratory efforts support/guide the activities of 2 postdoctoral fellows, 2 technicians, resident research fellows (1/year) and medical students (3-4/year). Areas of research include (a) role of neural influences of benign prostate growth, (b) central nervous system role in prostate differentiation, (c) diabetic/neuropathic mechanism of impotence, (d) nitric oxide synthetases role in erectile dysfunction, (e) peripheral neurologic control of endothelial derived nitric oxide, and (f) central neurologic control of erectile function. Each week (approximately 40 sessions/year) a formal laboratory meeting (60-90 minutes) is conducted. All personnel attend and present each week’s activities in a structured round table fashion. These sessions are both didactic and practical.
Laboratory Supervisor to Medical Students: 1993 – present
1-2 senior students perform research electives (8-12 weeks) in my laboratory each year. Structured didactics (see above) are supplemented with private tutorials (2-3 per rotation) each lasting about 60 minutes. In 1996 and in 1997 medical students were awarded a medical school research grant to work under my direct supervision. Additionally, each year a medical student was awarded an AFUD grant to work in my lab during the summer months.
Laboratory Mentor to Urology Research Fellows: 1990 – present
To date, 8 Urology residents have spent 1 year in my lab in fulfillment of their research requirements (1 per year). Each is assigned a project to conduct independently. Again, structured didactics are supplemented with 3-5 private tutorials (1 hour each) covering the abovementioned concepts. In addition, residents are expected to present their work at national/regional meetings and construct the first draft of a manuscript destined for peer-review publication. I supervise the construction of such work and provide the final edited version.
Urology Research Fellows
Richard Rento 1990 – 1991
Earl Cheng 1991 – 1992
Cletus Georges 1994 – 1995
Robert Brannigan 1995 – 1996
Christopher Gonzalez 1997 – 1998
John Hairston 1999 – 2000
Herbert User 2000 – 2001
Lloyd Granville 2001 – 2002
Lance Marr 2005 – 2006
Davis Viprasatik 2007 - 2008
Mentor to Postdoctoral Fellows: 1994 – 2004
To date, I have been advisor for 4 postdoctoral fellows (Xiobin Guan, Ph.D., Carol Podlasek, Ph.D., and Rudrani Ghosh, Ph.D.). Dr. Guan pursued (a) neurotrophin influences on prostate growth, (b) nerve growth factor gene expression in prostate tissue. Dr. Podlasek is pursuing studies on sonic hedgehog gene expression in prostate growth as well as nitric oxide synthase gene expression studies in penile tissues. Dr. Ghosh has studied neurotrophic factors which control prostate growth and development. Dr. Hong Bin looked at NOS in cavernous nerve injured animal models.
Mentor to Andrology Clinical Fellows: 2005-present
I have been mentor for many postdoctoral clinical fellows. Dr. Shane Russell was our first fellow (2005-2006) who came to us from Mayo Clinic, Rochester, MN. He is currently in private practice with an adjunct appointment in Clinical Urology at the University of Cincinnati. Our fellow for 2006-2007 was Dr Josh Modder (UC San Diego). He is private practice in Appleton, WI. The fellow for 2007-2008 was Dr. Tobias Kohler of the University of Minnesota. He is currently an Assistant Professor of Urology at Southern Illinois University School of Medicine in Springfield, IL. The fellow for 2008-2009 was Dr. Kenneth Poon of the University of British Columbia. He is currently an Assistant Professor of Clinical Urology at University of British Columbia in Vancouver, BC, Canada. The fellow for 2009-2010 was Dr. Eric Laborde from Louisiana State University in New Orleans, LA. As of July1, 2010 he is now Assistant Professor of Urology at Louisiana State University in New Orleans, LA. The fellow for 2010-2011 is Jason Hedges, MD-Ph.D, from Oregon Health & Science University.
The goal of this fellowship is to prepare physicians who are interested in erectile function and fertility for leadership roles in academic urology.
Seminars
Northwestern University Medical School: Department of Urology Grand Rounds - Lecture Series 1989-present. 3-4 hour-long lectures/year designed to provide an in-depth, system-oriented discussion of major topics in Urology. These sessions are attended by basic science and clinical faculty, residents, fellows and graduate/medical students.
Organized Ward Rounds: 1989 – present
10 Saturday AM sessions/year (3 hours per session) involving case presentations of all in-house GU patients at NMH, followed by a Socratic-style teaching and experience, and culminating with formal ward rounds with bedside didactics. These sessions are attended by Junior (3-5) and senior (1-2 surgical clerks and 2 members of the GU resident staff.
Urology IVP Conference
2-3 x/year - Uroradiology conferences (60 minute session) attended by GU faculty, resident staff, and Jr/Sr surgical clerks. These topics are clinically oriented and involve GU oncology, organic sexual dysfunction, nephrolithiasis, urinary diversion, and treatment of congenital urologic abnormalities.
Urology Resident Reading Conferences
2-3 sessions per year in which I select and direct an in-depth review of controversial urologic problems. I assign all topics, and coordinate the discussion that develops. These sessions are attended by all Urology residents as well as selected faculty and Jr/Sr surgical clerks.
Patient Services with Students and Residents: 1989 - present
I maintain an active clinical/surgical practice. The scope of these activities include (a) clinics four ‘half days’ per week (16 hours per week; 48 weeks per year); (b) 2 operating room days per week (48 weeks/year); and (c) residents and students benefit from intraoperative didactics of a clinical/technical nature; (d) students will frequently accompany me on informal “work rounds” in early AM and/or late PM.
From 1989 I have coverage responsibility at the VALMC (1 half/day/week). This entails responsibility for preoperative assessment and conduct of surgical procedures performed by chief residents in Urology.
Student Advising: 1989 – present
2-5 senior students/year have requested that I serve as their chief advisor with respect to applying for GU residency training programs. I meet with each student on 4-6 occasions (60 minutes each) to assist and finalize their application strategy.
15. RESEARCH GRANTS/CONTRACTS
Federal Grants (Principal Investigator):
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH-NIDDK
Title: Saw palmetto and Pygeum africanum on BPH Progression
Type of Award Research Grant (UO1)
Period of Support: September 30, 2002 – March 31, 2011
Total Direct Costs: $1,609,339
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH-NIDDK
Title: The Efficacy of TUMT and Neoadjuvant Finasteride for BPH
Type of Award: Research Grant (UO1)
Period of Support: September 30, 2001 – June 30, 2009
Total Direct Costs: $921,808
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH
Title: SPORE in Prostate Cancer, Project 4 (McVary): Molecular Mechanisms of Neuropathic Erectile Dysfunction.
Type of Award: NIH P50 CA 90386 (RO1)
Period of Support: June 1, 2001 – May 31, 2006
Total Direct Costs: $571,158
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH-NIDDK
Title: NOS Isoforms During Prostatic Development and BPH
Type of Award: Research Grant RO1
Period of Support: June 1, 2001 – May 31, 2002
Total Direct Costs: $66,150
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH-NIDDK
Title: Regulation of Prostate Growth by Neural Factors
Type of Award; Research Grant (RO1)
Period of Support: September 30, 1998 – July 31, 2002
Total Direct Costs: $457,725
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH-NIDDK
Title: Role of N.O.S. in Neuropathic and Endothelial Induced ED
Type of Award: Research Grant (RO1)
Period of Support: September 30, 1998 – August 31, 2003
Total Direct Costs: $719,570
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Veterans Administrative Lakeside Medical Center,
Department of Veterans Affairs
Title: Mechanisms of Diabetic Impotence
Type of Award: Merit Review Grant
Period of Support: September 1, 1997 - August 31, 2000
Total Direct Costs: $222,200
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH-NIDDK
Title: Medical Therapy of Prostatic Symptoms (MTOPS) A Six-Year, Double-Blind, Placebo-Controlled Study on the Effects of Doxazosin and Finasteride with Regards to BPH Treatment
Type of Award: Research Grant (UO1)
Period of Support: July 21, 1995 - March 31, 2003
Total Direct Costs: $1,838,267
Federal Grants (Co-Investigator):
Co-Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH
Title: Basic Science Training Grant in Urology
Type of Award: NRSA Institutional National Research Service Award
Period of Support: July 1, 2003 – June 30, 2008
Total Direct Costs: $974,792
Co-Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH
Title: Physician Training Program in Urologic Research
Type of Award: Training Grant
Period of Support: July 1, 1993 - June 30, 2000
Total Direct Costs: $44,188
FEDERAL RESEARCH GRANTS PENDING:
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH
Title: Neuropathic Factors in the Development and Progression of Prostate Growth in LUTS
Type of Award: RO1
Period of Support: pending
Total Direct Costs: $5,647,200
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH
Title: Trial of Lifestyle Intervention to Reduce LUTS/BPH via Autonomic Hyperactivity
Type of Award: RO1
Period of Support: pending
Total Direct Costs: $2,482,353
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: NIH
Title: Racial differences in the autonomic hyperactivity influences on LUTS/BPH following bariatric weight loss surgery.
Type of Award: RO1
Period of Support: pending
Total Direct Costs: $1,250,000
Industry Sponsored Grants (Principal Investigator):
Principal Investigator Kevin T. McVary, M.D.
Funding Agency: Eli Lilly and Company
Title: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion
Parameters in Men with Signs and Symptoms of BPH
Type of Award: Clinical
Period of Support: 1/19/09– Open
Total Direct Costs: $ 63,000
Principal Investigator Kevin T. McVary, M.D.
Funding Agency: Ferring, Inc
Title: A dose finding, multi-centre, double-blind, randomized, parallel, placebo-controlled trial to investigate efficiency and safety of degarelix in men with LUTS associated with BPH
Type of Award: Clinical
Period of Support: 2/19/10– Open
Total Direct Costs: $ 135,000
Principal Investigator Kevin T. McVary, M.D.
Funding Agency: Allergan, Inc.
Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Intraprostatic Administration of BOTOX® 200 U (Botulinum Toxin Type A) Purified Neurotoxin Complex to Treat LUTS/BPH
Type of Award: Clinical
Period of Support: 6/2/10– Open
Total Direct Costs: $ 87,000
Principal Investigator Kevin T. McVary, M.D.
Funding Agency: Johnson & Johnson Pharmaceutical Research
Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,
Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfunction Treated With a
Phosphodiesterase-5 Inhibitors
Type of Award: Clinical
Period of Support: 1/19/09– Open
Total Direct Costs: $ 87,000
Principal Investigator Kevin T. McVary, M.D.
Funding Agency: Eli Lilly and Company
Title: Prot# H6D-MC-LVHJ:A Phase 3, Randomized, Double-Blind, Study to Evaluate Daily Oral Doses of Tadalafil for 12 weeks in Men with LUTS and Prostatic Enlargement Secondary to BPH
Type of Award: Clinical
Period of Support: 1/9/09– Open
Total Direct Costs: $ 82,000
Principal Investigator Kevin T. McVary, M.D.
Funding Agency: Eli Lilly and Company
Title: A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with LUTS and Prostatic Enlargement Secondary to BPH
Type of Award: Clinical
Period of Support: 4/12/10– Open
Total Direct Costs: $ 120,000
Principal Investigator Kevin T. McVary, M.D.
Funding Agency: Medtronic Vascular
Title: The Zen Study: The Medtronic Zotarolimus-Eluting Peripheral Stent
System for the Treatment of Erectile Dysfunction in Males
with Sub-optimal Response to PDE5 Inhibitors
Type of Award: Clinical
Period of Support: 2/17/10– Open
Total Direct Costs: $ 120,000
Principal Investigator Kevin T. McVary, M.D.
Funding Agency: GlaxoSmithKline
Title: A Randomized, Placebo-Controlled, Double-Masked Clinical Trial Comparing Laser TURP with and without Neoadjuvant Dutasteride
Type of Award: Clinical
Period of Support: September 1, 2006 – Open
Total Direct Costs: $352,941
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Beckman Coulter, Inc.
Title: Concentration of Prostate Disease Serum Markers in Response to 5-alpha-Reductase Inhibitor Therapy
Period of Support: July 24, 2006 – Open
Total Direct Costs: $25,000
Principal Investigator Kevin T. McVary
Funding Agency: Lily ICOS - LVHG
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response and Safety of Tadalafil Once-a-Day Dosing for 12 wks in Men with Signs and Symptoms of BPH
Period of Support: September 1, 2006 – Open
Total Direct Costs: $71,000
Principal Investigator Kevin T. McVary
Funding Agency: Lilly ICOS - LVHK
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia
Period of Support: February 15, 2007 – Open
Total Direct Costs: $89,530
Principal Investigator Kevin T. McVary
Funding Agency: Zentaris
Title: Cetrorelix Pamoate Intermittent IM Dosage Regimens in Patients with Symptomatic BPH: A 1 Year Placebo Controlled Efficacy Study and Long-Term Safety Assessment
Period of Support: June 19, 2007 – Open
Total Direct Costs: 231,363
Principal Investigator Kevin T. McVary
Funding Agency: Lily ICOS – LVHG
Title: H6D-MC-LVHG(2) extension to H6D-MC-LVHG(a)
Period of Support: October 4, 2007 – Open
Total Direct Costs: 112,112
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Lilly ICOS
Title: An Open Label Study to Evaluate the Efficacy and Safety of Tadalafil
Administered “On Demand” to Men of Various Populations with Erectile Dysfunction [Protocol H6D-MC-LVFN(b)]
Period of Support: August 1, 2004 – December 31, 2006
Total Direct Costs: $12,000
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: ALZA Corporation
Title: An Open Label Study of the Long-Term Safety of Dapoxetine HCI in the Treatment of Rapid Ejaculation
Type of Award: Clinical Study
Period of Support: October 23, 2003 – December 31, 2006
Total Direct Costs: $63,660
Principal Investigator Kevin T. McVary, M.D.
Funding Agency: Pfizer, Inc.
Title: A Long-Term, Open Label, Multicenter Study of Darifenacin in Subjects with Overactive Bladder
Type of Award: Clinical Study
Period of Support: December 2, 2002 – December 31, 2006
Total Direct Costs: $33,925
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: American Medical Systems
Title: A Multi-Center Prospective Randomized Study of the Safety and Effectiveness of the Bioflow Degradable Urethral Stent
Type of Award: Clinical Study
Period of Support: February 1, 2002 – December 31, 2006
Total Direct Costs: $61,261
Principal Investigator: Kevin T. McVary
Funding Agency: Pfizer/AUA
Title: Fellowship in Support of Autonomic Hyperactivity in Erectile Dysfunction
Type of Award: Pfizer AUA Fellowship
Period of Support: July 1, 2006 – June 30, 2007
Total Direct Costs: $70,000
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: ALZA Corporation
Title: A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Efficacy and Safety of Dapoxetine HCI in the Treatment of Rapid Ejaculation
Type of Award: Clinical Study
Period of Support: November 26, 2002 – December 31, 2006
Total Direct Costs: $50,537
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Sanofi-Synthelabo Research
Title: The Long-Term Efficacy and Safety of Alfuzosin 10 mg OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients with BPH. A Two-Year, Randomized, Multicenter, Double-Blind Parallel Group, Placebo-Controlled Study
Type of Award: Clinical Study
Period of Support: June 1, 2001 – April 30, 2004
Total Direct Costs: $14,461
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Eli Lilly
Title: A Randomized Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of IC351 (LY450190) Administered on Demand to Patients with Erectile Dysfunction
Type of Award: Clinical Study
Period of Support: June 1, 2001 – May 4, 2003
Total Direct Costs: $30,960
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: ALZA Corporation
Title: A Placebo-Controlled, Double-Blind, Randomized, Crossover Study of the Efficacy and Safety of Dapoxetine HCI in the Treatment of Rapid Ejaculation
Type of Award: Clinical Study
Period of Support: October 1, 2001 – December 31, 2003
Total Direct Costs: $15,555
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Ono Pharmaceutical Co., Ltd.
Title: A Double-Blind Placebo-Controlled, Parallel-Group Safety and Efficacy Study Evaluating Three Dose Regimens of AIO-8507L, A Selective Alpha-Adrenergic Antagonist, in the Treatment of Benign Prostatic Hyperplasia
Type of Award: Clinical Study
Period of Support: June 1, 2001 – May 31, 2003
Total Direct Costs: $40,500
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Sanofi-Synthelabo Research
Title: A Double-Blind Randomized Parallel Group Study of Alfuzosin 10 mg OD Versus Placebo in the Management of Acute Urinary Retention in Patients with a First Episode Due to BPH
Type of Award: Clinical Study
Period of Support: June 1, 2001 – May 31, 2003
Total Direct Costs: $54,600
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Abbott Labs
Title: A Phase II Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men with Hormone Naïve Prostate Cancer that are Exhibiting Early Signs of Biochemical Failure (Protocol #MO1-366)
Type of Award: Clinical Study
Period of Support: October 10, 2001 – October 31, 2003
Total Direct Costs: $25,050
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Pfizer, Inc.
Title: A Phase III, Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Controlled Release Darifenacin vs Tolterodine in the Treatment of Patients with Overactive Bladder (#A1371001)
Type of Award: Clinical Study
Period of Support: April 12, 2000 – January 1, 2004
Total Direct Costs: $54,152
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Bayer
Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Fixed Dose, Parallel-Group, Six-Month Comparison Studies to Investigate the Efficacy and Safety of the Phosphodiesterase Type V Inhibitor BAY 38-9456 in Males with Erectile Dysfunction (#100249)
Type of Award: Clinical Study
Period of Support: May 18, 2000 – March 19, 2001
Total Direct Costs: $58,460
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Pfizer, Inc.
Title: A Phase III Multicenter, Open Label Continuation Study of the Long-Term Safety, Toleration, Compliance and Efficacy of Controlled Release Darifenacin in Subjects with Overactive Bladder
Type of Award: Clinical Study
Period of Support: January 1, 2000 – April 12, 2000
Total Direct Costs: $40,488
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Pfizer, Inc.
Title: A Study to Evaluate the Impact on Viagra on Treatment Satisfaction
Type of Award: Clinical Study
Period of Support: April 16, 1998 – October 12, 1999
Total Direct Costs: $12,000
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: Tap Holdings, Inc., M96-470
Title: Phase III Efficacy and Safety Study of 30 Fixed Doses of Apomorphine
SL Tablets Versus Placebo in Treatment of Male Erectile Dysfunction
Type of Award: Clinical Study
Period of Support: September 30, 1996 - January 1, 2000
Total Direct Costs: $59,782
Principal Investigator: Kevin T. McVary, M.D.
Funding Agency: TAP Pharmaceutical, Inc., M97-658
Title: Phase III Efficacy and Safety Study of Four Fixed Doses of Apomorphine SL Tablets Versus Placebo in the Treatment of Male Erectile Dysfunction
Type of Award: Clinical Study
Period of Support: June 1, 1997 – October 12, 1999
Total Direct Costs: $47,043
16. SCHOLARLY BIBLIOGRAPHY
a. Original, Peer-Reviewed Research Articles
1. Chen HH, Panella JS, Rochester D, Ignatoff JM, McVary KT: Non-Hodgkin Lymphoma of Ureteral Wall: CT Findings, J Comput Assist Tomogr 12(1):157-158, 1988.
2. Chung SK, McVary KT, McKenna KE: Sexual Reflexes in Male and Female Rats, Neurosci Lett 94(3):343-348, 1988.
3. McVary KT, O’Conor VJ: Transmission of NonA/NonB Hepatitis During Coagulation Pyelolithotomy, J Urol 141(4):923-925, 1989.
4. McVary KT, Maizels M: Urinary Obstruction Reduces Glomerulogenesis in the Developing Kidney: A Model in the Rabbit, J Urol 142(2 Pt 2):646-651, 1989.
5. McVary KT, Dalton DP, Blum MD: Acute Intestinal Pseudo-Obstruction (Ogilvie’s Syndrome) Complicating Radical Retropubic Prostatectomy, J Urol 141(5):1210-1212, 1989.
6. McKenna KE, Chung SK, McVary KT: A Model for the Study of Sexual Function in Anesthetized Male and Female Rats (Regulatory Integrative Comp Physiol) Am J Physiol, 261 (5 Pt 2):R1276-1285, 1991.
7. McVary KT, Grayhack JT: Transrectal Ultrasound in the Repair of the Post-Traumatic Urethra, J Urol 145(2):367-369, 1991.
8. Wang JM, McKenna KE, McVary KT, Lee C: Requirement of Innervation for Maintenance of Structural and Functional Integrity in the Rat Prostate, Biol Reprod 44(6):1171-1176, 1991.
9. Ellis WJ, Bauer KD, Oyasu R, McVary K: Flow Cytometric Analysis of Small Renal Tumors, J Urol 148(6):1774-1777, 1992.
10. Pearle MS, Oyasu R, Hidvegi D, Sutkowski D, Rademaker A, Cajulis R, Grayhack JT, McVary KT: Touch Preparation of Cytological Evaluation of Radical Prostatectomy Specimens, J Urol 152(1):124-128, 1994.
11. McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE: Growth of the Rat Prostate Gland is Facilitated by the Autonomic Nervous System, Biol Reprod 51(1):99-107, 1994.
12. Cajulis RS, Haines GK, Frias-Hidvegi D, McVary K: Interphase Cytogenetics as an Adjunct in Cytodiagnosis of Urinary Bladder Carcinoma: A Comparative Study of Cytology, Flow Cytometry and Interphase Cytogenetics in Bladder Washes, Analytical & Quant Cytol & Histol 16(1):1-10, 1994.
13. Kim ED, Blackburn D, McVary KT: Post-Radical Prostatectomy Penile Blood Flow: Assessment with Color Flow Doppler Ultrasound, J Urol 152(6 Part 2):2276-2279, 1994.
14. Cheng E, Rento R, Grayhack JT, Oyasu R, McVary KT: Reversed Seromuscular Flaps in the Urinary Tract in Dogs, J Urol 152(6 Pt 2):2252-2257, 1994.
15. Kim ED, McVary KT: Long-Term Results with Penile Vein Ligation for Venogenic Impotence, J Urol 153(3 Pt 1):655-658, 1995.
16. Kim ED, El-Rashidy R, McVary KT: Papaverine Topical Gel for Treatment of Erectile Dysfunction, J Urol 153(2):361-365, 1995.
17. Kim ED, McVary KT: Topical Prostaglandin-E1 for the Treatment of Erectile Dysfunction, J Urol 153(6):1828-1830, 1995.
18. Kim ED, McVary KT: Long Term Follow-Up of Treatment of Peyronie’s Disease with Plaque Incision, Carbon Dioxide Laser Plaque Ablation and Placement of a Deep Dorsal Vein Patch Graft, J Urol 153(6):1843-1846, 1995.
19. Oefelein MG, Colangelo LA, Rademaker AW, McVary KT: Intraoperative Blood Loss and Prognosis in Prostate Cancer Patients Undergoing Radical Retropubic Prostatectomy, J Urol 154(2 Pt 1):442-447, 1995.
20. Cajulis RS, Haines GK III, Frias-Hidvegi D, McVary K, Bacus JW: Cytology, Flow Cytometry, Image Analysis, and Interphase Cytogenetics by Fluorescence in Situ Hybridization in the Diagnosis of Transitional Cell Carcinoma in Bladder Washes: A Comparative Study, Diagnostic Cytopathology, 13:214-224, 1995.
21. Oefelein MG, Grayhack JT, McVary KT: Survival after Radical Retropubic Prostatectomy of Men with Clinically Localized High Grade Carcinoma of the Prostate, Cancer 76(12):2535-2542, 1995.
22. Steinberg J, Kim ED, McVary KT: A Surgical Approach to Penoscrotal Lymphedema, J Urol 156(5): 1770, 1996.
23. McVary KT, Rathnau CH, McKenna KE: Sexual Dysfunction in the Diabetic BB/WOR Rat: A Role of Central
Neuropathy, Am J Physiol 272 (1 Pt 2): (Regulatory Integrative Comp. Physiol. 41): R259-R267, 1997.
24. Wang X, Brannigan RE, Rademaker AW, McVary KT, Oyasu R: One Core Positive Prostate Biopsy is a Poor Predictor of Cancer Volume in the Radical Prostatectomy Specimen, J Urol 158(4): 1431-1435, 1997.
25. Oefelein MG, Smith ND, Grayhack JT, Schaeffer A, McVary KT: Long-Term Results of Radical Retropubic Prostatectomy in Men with High Grade Carcinoma of the Prostate, J Urol 158(4): 1460-1465, 1997.
26. Brannigan RE, Kim ED, Oyasu R, McVary KT: Comparison of Tunica Albuginea Substitutes for the Treatment of Peyronies Disease, J Urol 159(3): 1064-1068, 1998.
27. McVary KT, McKenna KE, Lee C: Prostate Innervation. The Prostate Supplement 8: 2-13, 1998.
28. Engel JD, McVary KT: Transurethral Alprostadil as Therapy for Patients Who Withdrew from or Failed Prior Intracavernosal Injection Therapy, Urology 51(5): 687-692, 1998.
29. Brannigan RE, Shin E, Rademaker A, Oyasu R, Huang CF, Pearle MS, McVary KT: The Usefulness of Touch Preparation Cytological Evaluation and Prostatic Capsule Involvement in Prediction of Prostate Cancer Recurrence, J Urol 160(5): 1741-1747, 1998.
30. Althof SE, Corty EW, Levine SB, Seftel A, Levine F, Burnett A, McVary K, Stecher V: The EDITS: Development of Questionnaires for Evaluating Satisfaction with Treatments for Erectile Dysfunction, Urology 53: 793-799, 1999.
31. Gonzalez CM, Bervig T, Podlasek C, Huang C-F, McKenna KE, McVary KT: Sildenafil Causes a Dose and Time Dependent Downregulation of Phosphodiesterase Type 6 Expression in the Rat Retina, Int J Impot Res 11: (Suppl 1), S9-S14, 1999.
32. McVary KT, Polepalle S, Riggi S, Pelham RW: Topical PGE-1/SEPA Gel for the Treatment of Erectile Dysfunction, J Urol 162(3 Pt 1): 726-730, 1999.
33. Jain P, Rademaker AW, McVary KT: Testosterone Supplementation for Erectile Dysfunction: Results of a Meta-analysis, J Urol 164: 371-5, 2000.
34. Gonzalez CM, Bervig T, Zelner D, Brannigan R, McKenna K, McVary KT: Protein and Gene Expression of Nitric Oxide Synthase Isoforms I and III in the Rat Penile Shaft, J Andrology 22(1): 54-61, 2001.
35. User H, Hoff F, McVary KT: Occult Retained Penile Prosthetic Fragments in Persistent Urogenital Infections, J Urol 165(2): 531-533, 2001.
36. Podlasek CA, Zelner D, Bervig TR, Gonzalez CM, McKenna KE, McVary KT: Characterization and Localization of NOS Isoforms in BB/WOR Diabetic Rat, J Urol 166(2): 746-755, 2001.
37. McVary KT, Carrier S, Wessells H: Smoking and Erectile Dysfunction: Evidence Based Analysis, J Urol 166(5): 1624-1632, 2001.
38. Podlasek CA, Gonzalez CM, Zelner D, Jiang HB, McKenna KE, McVary KT: Analysis of NOS Isoform Changes in Post Radical Prostatectomy Model of Erectile Dysfunction, Int J Impotence Res 13: (Suppl 5) S1-S15, 2001.
39. McVary KT, Foster H, Kusek J, Ramsdell J, Bautista O and the MTOPS Study Group. Self-Reported Sexual Function in Men with Symptoms of BPH – A MTOPS Study Report, Int J Impot Res 14: (Suppl): ACP1.32, 2002.
40. Eggener SE, Matschke MH, Nadler RB, McVary KT, Ignatoff JM, Campbell SC: Emphysematous Cystitis: Review of Current Management, Infections in Urology 15:12-14, 2002.
41. Podlasek C, Houston J, McKenna KE, McVary KT: Posterior Hox Gene Expression in Developing Genitalia, Evolution & Development 4(2): 142-63, 2002.
42. Rubenstein JN, McVary KT, Nadler RB, Gonzalez CM: Patient Positioning and Port Placement for Bilateral Hand-Assisted Laparoscopic Nephrectomy, Urology 59(3): 441-3, 2002.
43. User H, Hairston J, Zelner D, McKenna K, McVary KT: Penile Weight and Cell Subtype Specific Changes in a Post Radical Prostatectomy Model of Erectile Dysfunction.,J Urol 169(3): 1175-1179, 2003.
44. Podlasek CA, Zelner DJ, Jiang HB, Tang Y, Houston J, McKenna KE, McVary KT: Sonic Hedgehog Cascade is Required for Penile Postnatal Morphogenesis, Differentiation, and Adult Homeostasis, Biol. Reproduction 68(2): 423-438, 2003.
45. User H, Zelner DJ, McKenna KE, McVary KT. Microarray Analysis and Description of SMRI Gene in Rat Penis in a Post Radical Prostatectomy Model of Erectile Dysfunction, J Urol 170(1): 298-301, 2003.
46. Podlasek CA, Zelner DJ, Harris JD, Meroz CL, Tang Y, McKenna KE, McVary KT. Altered Sonic Hedgehog Signaling is Associated with Morphological Abnormalities in the Penis of the BB/WOR Diabetic Rat, Biol Reprod, 69(3): 816-827, 2003.
47. McVary KT. Sexual Dysfunction in Men with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Emerging Link, Brit J Urol 91(9): 770-771, 2003.
48. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The Long-term Effects of Doxazosin, Finasteride and the Combination on the Clinical Progression of BPH, New England Journal of Medicine 349(25): 2387-2398, 2003.
49. Padma-Nathan H, Christ G, Adaikan G, Becher E, Brock G, Carrier S, Carson C, Corbin J, Francis S, DeBusk R, Eardley I, Hedlund H, Hutter A, Jackson G, Kloner R, Lin CS, McVary K, McCullough A, Nehra A, Porst H, Schulman C, Seftel A, Sharlip I, Stief C, Teloken C. Pharmacology for Erectile Dysfunction, Journal of Sexual Medicine 1(2):128-40, 2004.
50. Carson C, McVary KT. BPH and Sexuality in the Aging Male, Contemporary Urology 16(11): 25-33, 2004.
51. McVary KT. Round Table: New Frontiers in Sexual Medicine. L11: The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms, Journal of Sexual Medicine 1(1):11-14, 2004.
52. Brown JS, Wessells H, Chancellor MB, Howards SS, Stamm WE, Stapleton AE, Steers WD, Van Den Eeden SK, McVary KT. Urologic Complications of Diabetes, Diabetes Care 28(1):177-85, 2005.
53. McVary KT. Rademaker A, Lloyd GL and Gann P. Autonomic Nervous System Overactivity in Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia, J Urol 174 (4 Pt 1): 1327-433, 2005.
54. McVary KT. Erectile Dysfunction and Lower Urinary Tract Symptoms Secondary to BPH, European Urology 47 (6):838-845, 2005.
55. McVary KT. Maintaining Sexual Health in the Andropause. “Managing Sexual Dysfunction in Mid-Life and Beyond-Overlooked Options, Accepted, Supplement to The Clinical Advisor, 2005.
56. McVary KT: Interrelation of Erectile Dysfunction and Lower Urinary Tract Symptoms, Drugs Today 41: (8): 527-536, 2005.
57. McVary KT. Alfuzosin for Symptomatic BPH: Long-Term Experience, J Urol 175 (1):35-42, 2006.
58. Kaplan SA, DeRose AF, Kirby RS, O’Leary MP and McVary KT: Beneficial Effects of Extended Release Doxazosin and Doxazosin Standard on Sexual Health, BJU International, 97 (3): 559-566, 2006.
59. McVary KT. Lower Urinary Tract Symptoms and Sexual Dysfunction: Epidemiology and Pathophysiology, BJU International 97: Issue s2, 23-28, 2006.
60. Helfand B, Mouli S, Dedhia R and McVary KT: Management of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with Open Prostatectomy – Results of a Contemporary Series, J Urol 176(6): 2257-61, 2006.
61. McVary KT: BPH: Epidemiology and Comorbidities, Am J Manag Care 12 (5 Suppl): S122-8, 2006.
62. McVary KT: Unexpected Insights into Pelvic Function Following Phosphodiesterase Manipulation – What’s Next for Urology?, European Urology 50: 1153-1156, 2006.
63. McVary KT: Quasi-Science or Quasimodo? European Urology, Accepted, October 2006.
64. McVary KT: Editorial Comment on: Effect of Nonsteroidal Anti-inflammatory Drug Use on the Incidence of Erectile Dysfunction, J Urol 175 (5): 1815-1816, 2006.
65. McVary KT: Baseline Factors as Predictors of Clinical Progression of Benign Prostatic Hyperplasia in Men Treated with Placebo – Comment, J Urol 175 (4): 1426, 2006.
66. McVary KT: Long-term Physical Activity and Lower Urinary Tract Symptoms in Men – Comment, J Urol 176 (6): 2550, 2006.
67. Erickson BA, Wysock JS, McVary KT and Gonzalez CM: Erectile Function, Sexual Drive and Ejaculatory Function after Reconstructive Surgery for Anterior Urethral Stricture Disease, BJU International 99(3): 607-11, 2007.
68. McVary KT, Monnig W, Camps JL Jr., Young JM, Tseng L-J and Van Den Eeden G: Sildenafil Citrate Improves Erectile Function and Urinary Symptoms in Men with Erectile Dysfunction and Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: A Randomized Double-Blind Trial, J Urol 177: (3) 1071-7, 2007.
69. Podlasek CA, Meroz CL, Tang Y, McKenna KE and McVary KT: Regulation of Cavernous Nerve Injury Induced Apoptosis by Sonic Hedgehog, Biol Reprod 76: 19-28, 2007.
70. McVary KT: Rebuttal from Authors re: Laurence A. Levine. Seeking Answers on the Quest for Effective Nonsurgical Treatment of Peyronie’s Disease, Euopean Urology 51: 601-604, 2007.
71. Russell S, Steers W and McVary KT: Systematic Evidence-Based Analysis of Plaque Injection Therapy for Peyronie’s Disease, European Urology 51: 640-647, 2007.
72. McVary K, Roehborn C, Kaminetsky J, Auerbach S, Wachs B, Young J, Esler A, Sides G, Denes B: Tadalafil Relieves Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH), Journal of Urology 177: (4) 1401-7, 2007.
73. McVary KT, Kaufman J, Young JM, Tseng LJ: Sildenafil Citrate Improves Erectile Function: A Randomized Double-Blind Trial with Open-Label Extension, International J Clinical Practice 61: (11) 1843-1849, 2007.
74. McVary KT: Clinical Practice. Erectile Dysfunction, New England Journal of Medicine 357: (24) 2472-81, 2007.
75. McVary KT: A Review of Combination Therapy in Patients with Benign Prostatic Hyperplasia, Clinical Therapeutics 29: (3) 387-398, 2007.
76. McVary KT: A Preliminary Study of JM-27: A Serum Marker that Can Specifically Identify Men with Symptomatic Benign Prostatic Hyperplasia – Comment. Journal of Urology 177 (2): 614, 2007.
77. McVary KT: Editorial Comment on: The Natural History of Peyronie’s Disease: An Ultrasonography-Based Study. European Urology 53: (3) 650-1, 2008.
78. Dedhia RC, Calhoun E and McVary KT: Impact of Phytotherapy on Utility Scores for Five BPH Tract Symptoms Health States. Journal of Urology, 179 (1): 220-5, 2008.
79. McVary KT and Russell S: Hands on Metabolic Syndrome and LUTS: An Emerging Relationship. Urology Times 35: 18-19, 2007.
80. Anderson CB, Helfand BT and McVary KT: Clinical Markers of Benign Prostatic Hyperplasia (BPH) Progression. Weill Medical College of Cornell University Reports on Men’s Urologic Health, volume 2, number 2, 2007.
81. McVary KT, Foley K, Long S, Sander S, Curtice T and Shah H: Identifying Patients with Benign Prostatic Hyperplasia through a Diagnosis of or Treatment for Erectile Dysfunction. Current Medical Research and Opinions, 24: (3) 775-784, 2008.
82. Dedhia R and McVary KT: Phytotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Journal of Urology, 179 (6): 2119-25, June 2008.
83. Chapple CR, Wein AJ, Abrams P, Dmochowski RR, Giuliano F, Kaplan SA, McVary KT, Roehrborn CG: Lower Urinary Tract Symptoms Revisited: A Broader Clinical Perspective. European Urology, 54: (3) 563-569, September 2008.
84. McVary KT: Editorial Comment on: Birth Weight, Abdominal Obesity and Risk of Lower Urinary Tract Symptoms, Journal of Urology, 2008.
85. McVary KT: Editorial Comment on: The Clinical Significance of Residual Urine – How Much is Too Much and When Should a Urologist Start Treatment? Journal of Urology, 180(1): 14, [Epub ahead of print], July 2008.
86. Anderson CB, Helfand BT, McVary KT: Holmium Laser Prostatic Resection for Patients Presenting with Acute Urinary Retention. British Journal of Urology International, 102 (11):1623, 2008.
87. McVary KT, Siegel RL, Carlsson M: Sildenafil Citrate Improves Erectile Function and Lower Urinary Tract Symptoms Independent of Baseline Body Mass Index or LUTS Severity. Urology, 72: 575-579, 2008.
88. O’Leary MP, Wei JT, Roehrborn CG, Miner M, BPH Registry and Patient Survey Steering Committee: Correlation of the International Prostate Symptom Score Bother Question with the Benign Prostatic Hyperplasia Impact Index in a Clinical Practice Setting. British Journal of Urology International, 101 (12): 1531-5, 2008.
89. Greco KA and McVary KT: The Role of Combination Medical Therapy in Benign Prostatic Hyperplasia. International Journal of Impotence Research, Suppl 3: S33-43, 2008.
90. Kohler TS, Modder JK, Dupree JM, Bush NC, McVary KT: Malleable Implant Substitution for the Management of Penile Prosthesis Pump Erosion: A Pilot Study. Journal of Sexual Medicine 6: (5) May, 2009.
91. Sejpal SV, Sathiaseelan V, Helenowski IB, Kozlowski JM, Carter MF, Nadler RB, Dalton DP, McVary KT, Lin WW, Garnett JE, Kalapurakal JA: Intraoperative Pubic Arch Interference During Prostate Seed Brachytherapy in Patients with CT-Based Pubic Arch Interference of < 1 CM. Radiotherapy and Oncology, 2009 May;73(5):950-7.
92. Helfand BT, Mongiu AK, Roehrborn CG, Donnell RF, Bruskewitz R, Kaplan SA, Kusek JW, Coombs L, McVary KT; MIST Investigators. Variation in institutional review board responses to a standard protocol for a multicenter randomized, controlled surgical trial. J Urol. 2009 Jun;181(6):2674-9. Epub 2009 Apr 16.
93. Penson DF, Wessells H, Cleary P, Rutledge BN, Lachin JM, Chan K-L, The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sexual Dysfunction and Symptom Impact in Men with Longstanding Type 1 Diabetes in the DCCT/EDIC Cohort. The Journal of Sexual Medicine July 2009, 6(7): 1969-1978.
94. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L: Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study. Journal of Urology 180: 1228-1234, October 2008.
95. Kohler TS, McVary KT: The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors. European Urology, 55 (1): 38-48, January 2009.
96. Van Den Eeden S, Sarma AV, Rutledge BN, Cleary PA, Kusek JW, Nyberg LM, McVary KT, Wessells H, Diabetes Control and Complications Trial/Epidemiology of Diabetes Research Group. Effect of Intensive Glycemic Control and Diabetes Complications on Lower Urinary Tract Symptoms in Men with Type 1 Diabetes: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care, 32 (4): 664-70, January 2009.
97. Kupelian V, Rosen RC, Link CL, McVary KT, Aiyer LP, Mollon P, Kaplan SA, McKinlay JB: Association of Urological Symptoms and Chronic Illness in Men and Women: Contributions of Symptom Severity and Duration – Results from the BACH Survey. Journal of Urology, 181 (2): 694-700, February 2009.
98. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA; BPH Registry and Patient Survey Steering Committee. Association of Sexual Dysfunction with Lower Urinary Tract Symptoms of BPH and BPH Medical Therapies: Results from the BPH Registry. Urology, 73 (3): 562-6, March 2009.
99. Helfand BT, Mongiu AK, Roehrborn CG, Donnell RF, Bruskewitz R, Kaplan SA, Kusek JW, Coombs L, McVary KT; MIST Investigators. Variation in institutional review board responses to a standard protocol for a multicenter randomized, controlled surgical trial. J Urol. 2009 Jun;181(6):2674-9.
100. Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, Mollon P, Tamimi N, Rosen RC, McKinlay JB: Association of Lower Urinary Tract Symptoms and the Metabolic Syndrome. Results from the Boston Area Community Health (BACH) Survey. J Urol. 2009 Aug;182(2):616-24; discussion 624-5.
101. Poon S, McVary KT: Dietary Patterns, Supplement Use and the Risk of Benign Prostatic Hyperplasia: A Review of the Economics, Definitions and Evidence. Curr Urol Rep. 2009 Jul;10(4):279-86.
102. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L. Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia. Eur Urol. 2009 Oct;56(4):727-36. Epub 2009 Apr 22.
103. Mongiu A, McVary KT. Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity. Current Urology Reports 2009, 10:247-253.
104. Helfand BT, Anderson CB, Kim DY, Vyas A and McVary KT: Post-Operative PSA and PSA Velocity Can Identify the Presence of Prostate Cancer Following Various Surgical Interventions for Benign Prostatic Hyperplasia. Urology. 2009 Jul;74(1):177-83.
105. Auffenberg G, Helfand BT, McVary KT. Established Medical Therapy for Benign Prostatic Hyperplasia. Urologic Clinics of North America. Urol Clin N Am 36; 443–459, 2009.
106. McVary KT: Unraveling the Pathophysiology between ED and LUTS. Urology. 2009 Jul;74(1):87.
107. I Eardley, C Donatucci, J Corbin, A El-Meliegy, K Hatzimouratidis, K McVary, R Munarriz, Sung Won Lee. Pharmacotherapy for Erectile Dysfunction. J Sex Med. 2010 Jan;7(1 Pt 2):524-40.
108. Alphs HA, Navai N, Kohler TS, McVary KT. Preoperative clinical and diagnostic characteristics of patients who require delayed IPP after primary Peyronies repair. J Sex Med. 2010 Mar;7(3):1262-8. Epub 2010 Jan 6.
109. McVary KT and Wessells H. Association of Intensive Glycemic Therapy and Prevalent Erectile Function in Men with Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Annals of Internal Med, provisional acceptance, 2010.
110. Lee J, McVary KT. A Negative Finding from a Single Center Study Led to Re-Design of a Large-Scale Clinical Trial of Phytotherapy for Benign Prostatic Hyperplasia (CT-09-0055). In Press, Journal of the Society for Clinical Trials, 2009.
111. Helfand BT, Blackwell R, McVary KT. Consequences of Switching 5-Alpha-Reducatase Inhibitors On Prostate Specific Antigen Velocity. J Urol. 2010 Jul;184(1):218-223. Epub 2010 May 16.
112. Helfand BT, Evans RM and McVary KT. A Comparison of the Frequencies of Medical Therapies for Overactive Bladder in Men and Women: Analysis of More Than 7.2 Million Aging Patients. Eur Urol. 2010 Apr;57(4):586-91. Epub 2009 Dec 28.
113. Helfand BT, Fought A, Manvar A, McVary KT. Determining the Utility of Recalled Lower Urinary Tract Symptoms. Urology. 2010 Aug;76(2):442-7. Epub 2010 Mar 25.
114. Helfand BT, Kim DY, Evans RM and McVary KT. Pharmacologic Therapies for OAB in Men: Analysis of Over 3.2 Million Americans. J Urol, Accepted 2010.
115. Helfand BT, Evans RM and McVary KT. Pharmacologic Treatment Patterns for Benign Prostatic Hyperplasia: an Analysis of Over 8.7 Million American Men. J Urol, In press 2010.
116. Maserejian NN, Giovannucci EL, McVary KT, McGrother C, McKinlay JB. Dietary Macronutrient and Energy Intake and Urinary Incontinence in Women. Am J Epidemiol. 2010 May 15;171(10):1116-25. Epub 2010 Apr 25
117. Erickson BA, Granieri MA, Meeks JJ, McVary KT, Gonzalez CM. Prospective Analysis of Ejaculatory Function after Anterior Urethral Reconstruction. J Urol. 2010 Jul;184(1):238-242. Epub 2010 May 16
118. Modi P, Helfand BT, McVary KT. Medications and Surgical Interventions for Benign Prostatic Hyperplasia are Potential Confounders of Prostate-Specific Antigen. Curr Urol Rep. 2010 Jul;11(4):224-7.
119. AlHussaini Z, McVary KT. Alpha-Blockers and Intraoperative Floppy Iris Syndrome: Ophthalmic Adverse Events Following Cataract Surgery. Curr Urol Rep. 2010 Jul;11(4):242-8.
120. Sea J, Poon KS, McVary KT. Review of exercise and the risk of benign prostatic hyperplasia. Phys Sportsmed. 2009 Dec;37(4):75-83
121. Lee J, Andriole G, Avins A, Crawford ED, Foster H, Kaplan S, Kreder K, Kusek J, McCullough A, McVary K, Meleth S, Naslund M, Nickel JC, Nyberg L, Roehrborn C, Dale Williams O, Barry M. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clin Trials. 2009 Dec;6(6):628-36. Epub 2009 Dec 9.
122. Sarma AV, Parsons JK, McVary K, Wei JT. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms--what do we know? J Urol. 2009 Dec;182(6 Suppl):S32-7.
123. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol. 2009 Dec;182(6 Suppl):S27-31.
124. Kupelian V, McVary KT, Barry MJ, Link CL, Rosen RC, Aiyer LP, Mollon P, McKinlay JB. Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey. Urology. 2009 May;73(5):950-7.
125. Hartman RJ Jr, Helfand BT, McVary KT. Outcomes of lateral retroperitoneal reservoir placement of three-piece penile prosthesis in patients following radical prostatectomy. Int J Impot Res. 2010 Jul;22(4):279-83. Epub 2010 Jun 24.
126. Helfand BT, Manvar AM, Auffenberg GB, Blackwell R, Hartman RJ, McVary KT. Holmium laser ablation and enucleation of the prostate: a pilot study of the hybrid technique. Can J Urol. 2010 Jun;17(3):5190-4.
127. McVary KT, Giovannucci EL, McKinlay JB, Maserejian, N. Dietary Macronutrient Intake and Lower Urinary Tract Symptoms in Women. Ann Epidemiol. Accepted 2010 November.
128. Wessells H, McVary KT, Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. J Urol. Accepted 2010 Dec. For print 2011, May.
129. Helfand BT, McVary KT, Meleth S, Sharp V, Foster H, Naslund M, Williams OD. The relationship between LUTS Severity attributed to BPH and sleep disturbance in the CAMUS Trial. J. Urol. Accepted 2011 Jan. For print 2011, June.
130. Maserejian N, McVary KT, et al. Intakes of Vitamins and Minerals in Relation to Urinary Incontinence, Voiding and Storage Symptoms in Women: A Cross-Sectional Analysis from the Boston Area Community Health Survey. Eur Urol. Accepted March 2011.
131. Wessells H, Penson DF, Cleary P, Rutledge BN, Lachin JM, McVary KT, Schade DS, Sarma AV; Diabetes
Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of Intensive Glycemic Therapy on Erectile Function in Men With Type 1 Diabetes. J Urol. 2011 May; 185 (5): 1828-1834.
132. Lee JY, Foster HE, McVary KT, Meleth S, Stavris K, Downey J, Kusek JW. Recruitment of Participants to a Clinical Trial of Botanical Therapy for Benign Prostatic Hyperplasia. J. Altern. Complement. Med. Epub ahead of print, 2011 May.
133. Gacci M, McVary KT, et al. Critical analysis of the relationship between sexual dysfunctions and LUTS due to BPH. Eur Urol. 2011 June.
b. Editorials, Reviews, Chapters, Books, Commentaries
Editorials (Invited)
1. McVary KT: Editorial: Durable Results Versus Endurable Procedures? J Urol 160(3 Pt 1): 783, 1998.
2. McVary KT. Management of Benign Prostatic Hyperplasia – Is There Anything New? AUA News, September/October issue, pp 1-4, 2002.
3. McVary KT. (Section Editor) Benign Prostatic Hyperplasia. In: Current Prostate Reports. (Editor-in-Chief: Steven A. Kaplan, Section Editors: Peter T. Scardino, Kevin T. McVary and Robert F. Donnell. Current Science, Inc. Publisher, Philadelphia, PA. Vol 2, No. 1, pp 21-35, 2003.
4. McVary KT. Editorial Comment: α-Blocker Use Is Associated With Decreased Risk of Sexual Dysfunction. Urology. 2009 Jul;74(1):87; author reply 87-8.
5. J Corbin, A El-Meliegy, K Hatzimouratidis, K McVary, R Munarriz, Sun Won Lee (S Korea). Pharmacotherapy for Erectile Dysfunction. In: C Donatucci, I Eardley, eds.
Editorials (Invited and Peer-Reviewed)
1. McVary KT. Review Finds New Evidence Linking Smoking and ED. In Urology Times, vol. 32, No. 2, Edited by Schenk A., Cleveland, OH: Advanstar Communications; page 7, 2003.
2. Helfand BT, McVary KT. Reply from Authors re: Roger Dmochowski. On Data Sets, Extrapolations, and Urologic Issues. doi:10.1016/j.eururo.2010.01.002. Eur Urol. 2010 Jan 14
3. McVary K, Tubaro A, De Nunzio C. The Motion: PDE5 Inhibitors are a Promising Therapy for Benign Prostatic Hyperplasia. Eur Urol. 2009 Jul 31.
Reviews (Invited)
1. McVary KT. Office-Based Transurethral Microwave Therapy. Current Urology Reports, Vol. 3, Issue 4, pp 267-268, 2002.
2. McVary KT. Medical Therapy for Benign Prostatic Hyperplasia Progression. Current Urology Reports, Vol. 3, Issue 4, pages 269-275, 2002.
3. Rubenstein JN, McVary KT. Transurethral Microwave Thermotherapy for Benign Prostatic Hyperplasia. Internat Braz J Urol 29 (3): 251-263, 2003.
4. McVary KT. Clinical Evaluation of Benign Prostatic Hyperplasia. Rev Urol 5 (suppl 4): S3-S11, 2003.
5. McVary KT. The MTOPS Trial: The Long-Term Effects of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. NEJM 349: 2387-98, 2003.
6. McVary KT. Sexual Function and αBlockers. Rev Urol 7 (suppl 8): S3-S11, 2005.
7. McVary KT. Alpha-Blockers in the Management of Acute Urinary Retention: Results of a Double-blind, Placebo-controlled Study. Current Urology Reports 6 (4): 241-2, 2005.
8. Podlasek CA, Meroz CL, Korolis H, Tang Y, McKenna KE, McVary KT. Sonic Hedgehog, the Penis and Erectile Dysfunction: A Review of Sonic Hedgehog Signaling in the Penis. Current Pharmaceutical Design 11 (31): 4011-4027, 2005.
9. Russell S, McVary KT. Lower Urinary Tract Symptoms and Erectile Dysfunction: Epidemiology and Treatment in the Aging Man. Current Urology Reports 6 (6): 445-53, 2005.
10. McVary KT: Saw palmetto for Benign Prostatic Hyperplasia. Current Urology Reports 7 (4): 251, 2006.
11. McVary KT. Minimally Invasive Option for BPH: Transurethral Needle Ablation. In: Update on Prostate Health. Highlights from the 2006 AUA Annual Meeting. Supplement to Urology Times, pp 5-6, Sept. 1, 2006.
12. Mouli S, McVary KT. Lower Urinary Tract Symptoms, Obesity and the Metabolic Syndrome. Curr Opin Urol. 20(1):7-12, 2010
13. Laborde EE, McVary KT. Medical management of lower urinary tract symptoms. Rev Urol. 2009 Fall;11(Suppl 1):S19-25.
Reviews (Invited and Peer-Reviewed)
1. McVary KT. Doxazosin for the Symptomatic Treatment of Benign Prostatic Hyperplasia. Current Urology Reports, Vol 4, Number 4, pp 267-268, 2003.
2. Gonzalez CM, McVary KT. The Role of Combination Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Current Urology Reports, Vol 4, Issue 4, pp 276-281, 2003.
3. McVary KT. Nonsteroidal Anti-inflammatory Drugs and Urinary Retention. The Lancet 367(9506): 195-6, 2006.
4. Kasturi S, Russell S, McVary KT. Metabolic Syndrome and Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Current Urology Reports 7(4): 288-92, 2006.
5. McVary KT. Clinical Scenario: Management of a Man with Voiding Complaints. Timely Topics in Medicine - Urology, November 1, 2006.
6. Kasturi S, Gonzalez C and McVary KT. The Role of Combination Therapy for LUTS Secondary to BPH. Current Urology Reports, Curr Urol Rep. 2003 Aug;4(4):276-81
Reviews (Peer-Reviewed)
1. Rubenstein JN, Wessels H, Carrier S, McVary KT. Erectile Dysfunction and Endothelial Disease: Is There a Role for Smoking? Sexual Dysfunction in Medicine, Vol. 2, No. 4, pp 94-98, 2001.
2. Podlasek CA, Houston J, McKenna KE, McVary KT. Posterior Hox Gene Expression in Developing Genitalia. In: Evolution and Development (Special Edition), Vol. 4, No. 2, pp 142-163, 2002.
3. Yap RL, McVary KT. Topical Agents and Erectile Dysfunction: Is There a Place? Current Urology Reports, Vol. 3, Issue 6, pp 471-476, 2002.
4. Yap RL, McVary KT. Smoking and Erectile Dysfunction: How Strong a Link? Contemporary Urology 15 (3), 34-40, 2003.
5. McVary KT. The Medical Therapy of Prostatic Symptoms Trial. Current Urology Reports, Vol. 5, Issue 4, pp 249-50, 2004.
6. McVary KT, McKenna KE. The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms: Epidemiological, Clinical, and Basic Science Evidence. Current Urology Reports 5: (4): 251-7, 2004.
7. Andersson, KE, De Groat, WC, McVary KT, Lue, TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. Neurology and Urodynamics. 2011.
Chapters
1. McVary KT . Lymphoproliferative Disease and the Genitourinary Tract. In: AUA Update Series, Ball TP, (Ed) Houston: American Urological Association, Vol 22, pp 170-176, 1991.
2. McVary KT, Grayhack JT. Stage A2 Prostatic Adenocarcinoma of the Prostate. In: Current Therapy in Genitourinary Surgery, 2nd edition, Resnick MI, Kirsh ED, (Ed) St. Louis, MO: BC Decker, pp 105-109, 1991.
3. McVary KT. Urinary Fistulas. In: Review of Adult and Pediatric Urology, 3rd edition, Gillenwater JJ, Grayhack JT, Howards SS, and Duckett JW, (Ed) Mosby Publishing Co., St. Louis, Chapter 28, pp 104-107, 1996.
4. McVary KT, Marshal FF. Urinary Fistulas. In: Adult and Pediatric Urology, 3rd edition, Gillenwater JJ, Grayhack, JT, Howards SS, and Duckett JW, (Ed), Mosby Publishing Co., Philadelphia, Chapter 28, Vol. 2, pp 1355-1377, 1996.
5. Georges C, McVary KT. Rehabilitation of Prostate Cancer. In: Palliative Care and Rehabilitation of Cancer Patients, (Ed) von Gunten C, Kluwer Academic Publishers, Cancer Treatment Research, Vol 100, pp 135-60, 1999.
6. McVary KT, Grayhack JT. Benign Prostatic Hyperplasia (BPH). In: Encyclopedia of Reproduction, Desjardins C, Kumbil E, and Neill JD (Ed), Academic Press, Vol. 1, pp 349-357, 1999.
7. McVary KT. Erectile Dysfunction. In: Harrison’s Principles of Internal Medicine, Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, and Jameson JL (Ed) McGraw-Hill Publishers, 15th edition, Chapter 51, pp 291-295, 2001.
8. McVary KT, Hairston J. Topical and Intraurethral Therapy. In: Male Sexual Function: A Guide to Clinical Management. Published in the Current Clinical Urology Series. Mulcahy J (Ed), The Humana Press, Inc, Totowa, NJ, Chapter 12, pp 225-243, 2001.
9. Rubenstein J, McVary KT. Transurethral Microwave Therapy of the Prostate (TUMT). emedicine journal, Vol. 2, No. 6, pp 1-20, 2001.
10. McVary KT, Marshall FF. Urinary Fistulas. In: Adult and Pediatric Urology, Gillenwater JJ, Grayhack, JT, Howards SS and Mitchell ME (Ed), Lippincott Williams and Wilkins Publishers, Philadelphia, Vol 2, 4th edition, pp 1271-1295, 2002.
11. Grayhack JT, McVary KT, Kozlowski JM. Benign Prostatic Hyperplasia. In: Adult and Pediatric Urology, Gillenwater JJ, Grayhack JT, Howards SS and Mitchell ME (Ed), Lippincott Williams and Wilkins Publishers, Philadelphia, Vol 2, 4th edition, pp 1401-1470, 2002.
12. Lloyd GL, McVary KT. Infrapubic Implantation of the Three-Piece Inflatable Penile Prosthesis. In: Atlas of Urologic Clinics of North America. Mulcahy JJ (Ed), W. B. Saunders Co., Philadelphia, PA, Vol. 10, Issue 2, pp 163-168, 2002.
13. McVary KT. Management of Benign Prostatic Hypertrophy. Edited by Kevin T. McVary. Humana Press Inc., Totowa, New Jersey, pp 1-269, 2004.
14. Stern JA, Fitzpatrick JM, McVary KT. Prostate Anatomy and Causative Theories, Pathophysiology, and Natural History of Benign Prostatic Hyperplasia. In: Management of Benign Prostatic Hypertrophy. Current Clinical Urology Series. Chapter 1, pp 1-19, McVary KT (Ed). Humana Press Inc., Totowa, New Jersey, 2004.
15. Rubenstein JN, McVary KT. Transurethral Microwave Thermotherapy. In: Management of Benign Prostatic Hypertrophy. Current Clinical Urology Series. Chapter 8, pp 109-139, McVary KT (Ed). Humana Press Inc., Totowa, New Jersey, 2004.
16. McVary KT. Sexual Dysfunction. In: Harrison’s Principles of Internal Medicine, Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL and Jameson JL, 16th edition, Chapter 43, McGraw-Hill Publishers, pp 271-275, 2004.
17. Hairston JC, Becher E, McVary KT. Topical and Intraurethral Therapy. In: Male Sexual Function: A Guide to Clinical Management. Published in the Current Clinical Urology Series. Mulcahy J (Ed), The Humana Press, Inc, Totowa, NJ, Chapter 14, pp 301-319, 2005.
18. Helfand BT, Moon T, McVary KT. Medical Management of Benign Prostatic Hyperplasia. In: Atlas of the Prostate. Scardino PT and Slawin KM (Ed), 3rd Edition, Chapter 3, Current Medicine Group LLC, Philadelphia, PA, pp 25-52, 2006.
19. Dedhia R.C., McVary KT. Botanicals for Benign Prostatic Hyperplasia. In: The Encyclopedia of Herbal Medicine in Clinical Practice. Watson RR and Preedy VR (eds), “Botanical Medicine in Clinical Practice”, CAB International, Wallingford, UK, Chapter 28, pages 256-264, 2008.
20. McVary KT. Sexual Dysfunction. In: Harrison’s Principles of Internal Medicine, Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL and Jameson JL (Ed), 17th edition, Section 8, Chapter 49, McGraw-Hill Publishers, 2008.
21. Park JK, Kohler TS, McVary KT: Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, and Sexual Dysfunction. In: Current Bladder Dysfunction Reports. Current Medicine Group LLC, Philadelphia, PA, 3: pp xx-xx, in press, 2010.
22. Modder J, Podlasek CA, McVary KT. Pathophysiology of Erectile Dysfunction Following Radical Prostatectomy. In: Sexual Function in the Prostate Cancer Patient, Mulhall J (Ed), Humana Press, Totowa, NJ, 2009; 268: 34-47.
23. Helfand BT and McVary KT: Complications of Minimally Invasive Treatments for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. In: Complications in Urologic Surgery, Loughlin KR (Ed), Chapter 30, in press, 2007.
24. Modder JK and McVary KT: Hinman’s Atlas of Urologic Surgery, 3rd Edition. Section XIV: Prostate: Benign Disease. Chapter 93: Suprapubic Prostatectomy, in press 2007.
Books:
1. McVary KT and Helfand BT: Contemporary Diagnosis and Management of the Enlarged Prostate. In: Handbooks in Health Care Co., Newtown, PA, pp 1-248, 2007.
1. McVary KT: Contemporary Treatment of Erectile Dysfunction. Humana Press, pp. 1-287, 2011.
Commentaries
1. McVary KT, Rademaker AW: Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate: IV. Anti-Androgen Treated Patients (letter), J Urol 144(6):1485-1486, 1990.
2. McVary KT: A Test for the Identification of Relevant Sympathetic Nerve Fibers During Nerve Sparing Retroperitoneal Lymphadenectomy (Letter), J Urol 148:1450-1452, 1992.
3. Helfand BT, McVary KT. Reply from Authors re: Roger Dmochowski. On Data Sets, Extrapolations, and Urologic Issues. Eur Urol. In press. doi:10.1016/j.eururo.2010.01.002. Eur Urol. 2010 Jan 14. [Epub ahead of print]
c. Case Reports, Technical Notes, Letters: NA
d. Proceedings and Non-Refereed Papers
1. McVary KT. Sexual Dysfunction: In: Proceedings of the Third Annual Spring Clinical Nephrology, Meetings of the National Kidney Foundation, Inc., Published by the National Kidney Foundation, pp 99-102, 1994.
2. McVary KT. The Role of Uroflow in the Evaluation of Men with Symptomatic Bladder Neck
Outlet Obstruction, AUA News, Jan/Feb, Vol 3, No. 1, pp 1-4, 1998.
3. Virag R, Becher E, Carrier S, Govier F, McVary K, McMahon HC and Porst H. Local Pharmacological Treatment Modalities. In: Erectile Dysfunction. Committee 9, pp 305-354. Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H and Rosen R (Ed). 1st International Consultation on Erectile Dysfunction, July 1-3, 1999, Paris. Co-Sponsored by World Health Organization (WHO) – International Society for Impotence Research Societe Internationale d’Urologie. Plymbridge Distributors, Ltd Distributor, United Kingdom, 2000.
4. Padma-Nathan H, Christ G, Adaikan G, Becher E, Brock G, Carrier S, Carson C, Corbin J, Francis S, DeBusk R, Eardley I, Hedlund H, Hutter A, Jackson G, Kloner R, Lin C, McVary K, McCullough A, Nehra A, Porst H, Schulman C, Seftel A, Sharlip I, Stief C, Teloken C. Pharmacotherapy for Erectile Dysfunction. In Sexual Medicine, Sexual Dysfunctions in Men and Women. Committee 14, Chapter 15, pp 503-565. Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F (Ed). 2nd International Consultation on Sexual Dysfunction – Paris. Co-Sponsored by International Consultation on Urological Diseases (ICUD), International Society of Urology (SIU) and International Society for Sexual and Impotence Research (ISSIR), 2004.
e. Software, World Wide Web-Based Publications, Exhibits, Audiovisual or other Teaching Material
1. Update on Sexual Dysfunction. Audio-Digest Urology, Vol. 21, Number 6, Side B, 1998.
2. Update on Emerging Technologies. Audio-Digest Urology, Vol 22, Number 12, Side A, 1999.
3. BPH: Pharmacologic Management. Audio-Digest Urology, Vol 24, Number 5, 2001.
4. Minimally Invasive Treatments for BPH. AUA Topics in Urology Audio Series, 2003.
5. McVary KT. George Washington University Medical Center’s multimedia continuing medical education projects entitled The Virtual Prostate and New Guidelines for Treatment of BPH. Audio WebCalls.
6. Merck & Co. eHealth Seminars. Electronic Remote Speaker Program on Selected Options in the Treatment of BPH.
7. Doctor on Call LIVE. Audio/Internet Presentations on Novel Therapeutic Options and Management Strategies for Treating Erectile Dysfunction. Sponsored by Annenberg Center for Health Sciences at Eisenhower and CogniMed, Inc.
8. Doctor on Call LIVE. Vol. 3, No. 9 Session “Clinical Correlation Between Erectile Dysfunction and Lower Urinary Tract Symptoms”.
9. ALZA Web Conference on Dapoxetine Clinical Program Update in Conjunction with Hewlett Packard Media Solutions.
10. Modern Treatment Options for the Treatment of BPH - Sanofi Slide Set
11. Boehringer Ingelheim BPH Beyond Urology Expert Slide Set
12. Combination Therapy for BPH/LUTS – Slide Sets – Merck Slide Set
13. Overlapping Issues of Male LUTS and Sexual Dysfunction. Curatio CME Institute, , September 2007.
f. Patents: NA
g. Abstracts (Past 6 Years)
1. McVary KT, Foley J, Bautista OM and Kusek J (2003) The Long Term Effects of Doxazosin, Finasteride, and the Combination of Both on Sexual Function in Men Participating in the MTOPS Study. American Urological Association 98th Annual Meeting, Chicago, IL, Journal of Urology 169: No. 4, 475, Abstract #1783.
2. McVary KT, Foley J, Bautista OM, Kusek J. (2003) Association of Lower Urinary Tract Symptoms (LUTS) with Sexual Function in Men Participating in a Clinical Trial of Medical Therapy for Benign Prostatic Hyperplasia. American Urological Association 98th Annual Meeting, Chicago, IL, Journal of Urology 169: No. 4, 322, Abstract #1252.
3. McVary KT, Foley J, Bautista OM and Kusek J. (2003) Association of LUTS with Sexual Function in Men Participating in a Clinical Trial of Medical Therapy for BPH. Journal of Urology 169: No. 4, 346, Abstract #DP30.
4. Podlasek CA, Zelner DJ, McKenna KE, McVary KT. (2003) Sonic Hedgehog Signaling is Disrupted in a Post Radical Prostatectomy Model of Erectile Dysfunction. American Urological Association 98th Annual Meeting, Chicago, IL, Journal of Urology 169: No. 4, 305, Abstract #1186.
5. Ghosh R, Podlasek C, McKenna KT, McVary KT. (2003) Unilateral Pelvic Ganglionectomy Causes Significant Increase in Nerve Growth Factor Expression in the Rat Ventral Prostate. American Urological Association 98th Annual Meeting, Chicago, IL . Journal of Urology 169: No. 4, #287, Abstract 1114.
6. Podlasek CA, Zelner DJ, McKenna KE, McVary KT. (2003) Morphological Changes and Altered NOS Isoform Distribution in the BB/WOR Diabetic Rat Prostate. American Urological Association 98th Annual Meeting, Chicago, IL, Journal of Urology 169: No. 4, 285, Abstract #1108.
7. Donatucci C, Pommerville P, Niederberger C, Thibonnier M, Segerson T, McVary KT and Hellstrom WG (2003) Vardenafil Improved Patient Satisfaction with Erection Hardness, Orgasmic Function and Sexual Experience in Men with Erectile Dysfunction. Journal of Urology 169: No. 4, 246, Abstract #950.
8. Calhoun B, Welshman E, Cashy J, Cella D and McVary KT (2004) Relationship between Objective and Subjective Assessments of Erectile Dysfunction. American Urological Association Annual Meeting, San Francisco, CA, Journal of Urology 171: No. 4, 232, Abstract #878.
9. Roehrborn CG, Kusek JW, Nyberg LM, Noble W, Bautista O, McVary KT, Slawin KM and Slawin KM (2004) Impact of Baseline Symptom Severity on Threshold Changes to Trigger Crossing Over to Active Therapy in MTOPS Trial. American Urological Association Annual Meeting, San Francisco, CA, Journal of Urology 171: No. 4, 241, Abstract #910.
10. Roehrborn CG, McConnell JD, Kusek JW, Nyberg LM, Slawin KM, McVary KT, Dixon CM, Kaplan SA and The MTOPS Investigator Group (2004) Impact of Baseline PSA and TRUS Volume on Longitudinal Changes in IPSS and Maximum Flowrate in MTOPS. American Urological Association Annual Meeting, San Francisco, CA, Journal of Urology 171: No. 4, 241, Abstract #911.
11. McVary KT, Foley-Brooke J, Slawin KM and Kusek JW. (2004) Long Term Effects of Doxazosin, Finasteride, and the Combination on Sexual Function in Men Participating in the MTOPS Study. American Urological Association Annual Meeting, San Francisco, CA, Journal of Urology 171: No. 4, 315, Abstract #1194.
12. Podlasek CA, Zelner DJ, Korolis HL, McKenna KE and McVary KT (2004) Morphological Changes and Altered NOS Isoform Distribution in the BB/WOR Diabetic Rat Prostate. American Urological Association Annual Meeting, San Francisco, CA, Journal of Urology 171: No. 4, 347, Abstract #1317.
13. Wood DR, Podlasek CA, Ghosh R, McKenna KE and McVary KT (2004) Altered ROCK-I and ROCK-II Expression in Diabetic Model of Erectile Dysfunction: The BB/WOR Rat. American Urological Association Annual Meeting, San Francisco, CA, Journal of Urology 171: No. 4, 372, Abstract #1413.
14. Podlasek CA, Tang Y, Meroz CL, Korolis HL, McKenna KE and McVary KT (2004) Decreased Sonic Hedgehog Protein, Erectile Dysfunction and Cavernous Nerve Injury. American Urological Association Annual Meeting, San Francisco, CA, Journal of Urology 171: No. 4, 376, Abstract #1427.
15. McVary KT (2004) Erectile Dysfunction in Prostate Cancer Patients: A Translational Project. 12th SPORE Investigators’ Workshop, Baltimore, MD.
16. Erickson BA, Wysock JS, Jang TL, McVary KT and Gonzalez CM (2005) Male Sexual Function after Urethral Reconstructive Surgery for Stricture Disease. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173: No. 4, 36, Abstract #132.
17. McVary KT, Podlasek CA, McKenna KE and Wood D (2005) Intrinsic and Extrinsic Apoptotic Pathways are Employed Neuropathic and Diabetic Models of Erectile Dysfunction. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 284, Abstract #1046.
18. Podlasek CA, Wood D, Tang Y, McKenna KE and McVary KT (2005) Rock-II Protein Abundance is Increased in Diabetic and Cavernous Nerve Injured Penes. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 284, Abstract #1047.
19. Podlasek CA, Meroz CL, Korolis H, McKenna KE and McVary KT (2005) Neural Regulation of Sonic Hedgehog in the Penis. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 286, Abstract #1054.
20. Rosen R, McVary KT, Nuckolls J, Payne R, Seftel AD, Steers WD and the BPH Registry Steering Committee. (2005) American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 337, Abstract #1242.
21. Roehrborn CG, Kaplan SA, Noble WD, Lucia MS, Slawin KM, McVary KT, Kusek JW and Nyberg LM (2005) The Impact of Acute or Chronic Inflammation in Baseline Biopsy on the Risk of Clinical Progression of BPH: Results from the MTOPS Study. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 284, Abstract #1047. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 346, Abstract #1277.
22. McVary KT, Rademaker A and Gann P (2005) Autonomic Nervous System Overactivity in Men with LUTS Secondary to BPH. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 349, Abstract #1287.
23. Roehrborn CG, McVary KT, Slawin KM, Noble WD, Kusek JW and Nyberg LM (2005) Improved Correlations between Serum PSA and Prostate Volume Measures in the Biopsy Subset of Patients in MTOPS. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 349, Abstract #1288.
24. McVary KT, Helfand B, Roehrborn CG, Donnell RF, Bruskewitz RC, Kaplan SA, Kusek JW, Coombs L and Slawin KM (2005) Variation in IRB Review of a Multi-Center Clinical Trial Study Protocol. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 377, Abstract #1389.
25. Podlasek CA, Meroz CL, Tang Y, McKenna KE and McVary KT (2005) Altered NOS Isoform Abundance and Distribution in BB/WOR Diabetic Prostate. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 386, Abstract #1425.
26. Roehrborn CG, Kaplan SA, Lee MW, Slawin KM, McVary KT, Kusek JW and Nyberg LM (2005) Baseline Post Void Residual Urine Volume as a Predictor of Urinary Outcomes in Men with BPH in the MTOPS Study. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 443, Abstract #1638.
27. Slawin KM, Roehrborn CG, McConnell JD, Kreder KJ Jr, Jacobs SC, McVary KT, Foster HE, Clarke HS Jr, Milam DF, Noble WD, Nyberg LM, Kusek JW and Kattan MW (2005) Development of a Nomogram to Predict Symptom Progression with or without Medical Therapy in Men with BPH Based on Data from the MTOPS Trial. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 444, Abstract #1639.
28. Roehrborn CG, Kaplan SA, Lee MW, Slawin KM, McVary KT, Kusek JW and Nyberg LM (2005) A Comparison of Men with a Four Point Increase – Confirmed or not Confirmed – In the AUA Symptom Score – Results from the MTOPS Study. American Urological Association Annual Meeting, San Antonio, TX, Journal of Urology 173, No. 4, 445, Abstract #1644.
29. McVary KT (2005) Baseline Post-Void Residual Urine Volume as a Predictor of urinary Outcomes in Men. 79th Annual North Central Section AUA, Inc., Chicago, IL
30. McVary KT (2005) Metabolic Syndrome/Autonomic Nervous System Overactivity in Men with LUTS Secondary to BPH. 79th Annual North Central Section AUA, Inc., Chicago, IL
31. McVary KT (2005) Intrinsic and Extrinsic Apoptotic Pathways are Employed in Neuropathic and Diabetic Models of Erectile Dysfunction. 79th Annual North Central Section AUA, Inc., Chicago, IL.
32. McVary KT (2005) Inconsistency in IRB Approval for a Common NIH Minimally Invasive Protocol. 79th Annual North Central Section AUA, Inc., Chicago, IL.
33. McVary KT, Rosen R, Ho K-F, Kell S (2005) Effect of Dapoxetine on Intravaginal Ejaculatory Latency Time in Men with Lifelong and Acquired Premature Ejaculation. Sexual Medicine Society North America Meeting, New York, NY.
34. McVary KT, Helfand B, Roehrborn C, Kaplan S, Crawford D, Donnell R, Bruskewitz R (2005) Inconsistency in IRB Approval for a Common NIH Minimally Invasive Protocol. Sexual Medicine Society North America Meeting, New York, NY.
35. McVary KT, Podlasek CA, McKenna KE, Wood D (2005) Intrinsic and Extrinsic Apoptotic Pathways are Employed in Neuropathic and Diabetic Models of Erectile Dysfunction. Sexual Medicine Society North America Meeting, New York, NY.
36. McVary KT (2006) Immediate Post-Treatment Care and the Economic Outcomes in BPH Patients Undergoing an Office-Based Transurethral Microwave Thermotherapy (TUMT) or Transurethral needle Ablation Procedure (TUNA). American Urological Association Annual Meeting, Atlanta, GA Journal of Urology 175, No. 4, 3, Abstract #8
37. McVary KT, Swierzewski MJ, Monnig WB, Rosenberg S, Bowler IA, Tseng L-J and Siegel RL (2006) Sildenafil Improves Erectile Function and Concomitant Lower Urinary Tract Symptoms in Men. American Urological Association Annual Meeting, Atlanta, GA Journal of Urology 175, No. 4, 298, Abstract #920.
38. Rosen RC, Marks LS, McVary KT, Roehrborn CG, O’Leary MP and Lue TF (2006) Association between Ejaculatory Dysfunction and Therapy Among Men Enrolled in the BPH Registry and Patient Survey. American Urological Association Annual Meeting, Atlanta, GA Journal of Urology 175, No. 4, 298, Abstract #921.
39. Russell ST, Steers WD and McVary KT (2006) Systemic Evidenced-Based Analysis of Injection Therapy for Peyronie’s Disease. American Urological Association Annual Meeting, Atlanta, GA Journal of Urology 175, No. 4, 321, Abstract #995.
40. McVary KT, Podlasek CA, Wood D and McKenna KE (2006) Apoptotic Pathways are Employed in Neuropathic and Diabetic Models of Erectile Dysfunction. American Urological Association Annual Meeting, Atlanta, GA Journal of Urology 175, No. 4, 387, Abstract #1203.
41. Kundu S, Roehl KA, Loeb S, Gashti SN, Smith N, McVary KT and Catalona WJ (2006) Could Laser Vaporization of the Prostate for BPH Compromise Prostate Cancer Detection? American Urological Association Annual Meeting, Atlanta, GA Journal of Urology 175, No. 4, 462, Abstract #1432.
42. Kaplan SA, Coombs LP, Roehrborn CG, Bruskewitz R, Crawford ED, McVary KT, Kusel JW, Nyberg LM (2006) Factors Responsible for Failure to Recruit in a Clinical Trial Comparing Minimally Invasive Surgical Therapy with Combination Drug Treatment for Benign Prostatic Hyperplasia. American Urological Association Annual Meeting, Atlanta, GA Journal of Urology 175, No. 4, 487, Abstract #1509.
43. Roehrborn CG, McVary KT, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Ester A, Sides GD, Denes BS (2006) The Efficacy and Safety of Tadalafil Administered Once a Day for Lower Urinary Tract Symptoms (LUTS) in Men with Benign Prostatic Hyperplasia (BPH). American Urological Association Annual Meeting, Atlanta, GA Journal of Urology 175, No. 4, 527, Abstract #1636.
44. McVary KT, Camps J, Henry GD, Conner SD and Tseng L-J (2006) Sildenafil Improves Erectile Function and Urinary Symptoms in Men with Erectile Dysfunction and Concomitant Lower Urinary Tract Symptoms. American Urological Association Annual Meeting, Atlanta, GA Journal of Urology 175, No. 4, 527, Abstract #1637.
45. Dedhia RC, Welshman E, Calhoun EA and McVary KT (2006) Impact of Phytotherapy Use on Utility Scores in Patients with BPH/LUTS. American Urological Association Annual Meeting, Atlanta, GA Journal of Urology 175, No. 4, 529, Abstract #1642.
46. McVary KT (2007) Efficacy of Tadalafil Dosed Once a Day to Treat Erectile Dysfunction in Men with Comorbid Moderate or Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. American Urological Association Annual Meeting, Anaheim, CA, Abstract #956).
47. McVary KT (2007) Vardenafil in the Treatment of Symptomatic Benign Prostatic Hyperplasia.
American Urological Association Annual Meeting, Anaheim, CA, Abstract #1565).
48. McVary KT (2007) Improvement with Sildenafil in Men with Moderate and Severe Lower Urinary Tract Symptoms. American Urological Association Annual Meeting, Anaheim, CA, (Abstract #1547).
49. McVary KT (2007) Improvement with Sildenafil in Men with Moderate and Severe Urinary Tract Symptoms. North Central Section of the American Urological Association Meeting, Hollywood, FL, (Abstract #90).
50. McVary KT (2008) Tadalafil Administered Once Daily in the Treatment of Men with Lower Urinary Tract Symptoms Secondary to BPH: A Dose-Finding Study. Sexual Medicine Society of North America, Toronto, Canada.
17. PRESENTATIONS
1. Treatment of Lower Urinary Tract Symptoms. University of Illinois at Chicago – Grand Rounds. January 20, 1999.
2. Current Approach to Male Sexual Dysfunction. The Year in Internal Medicine. Thirty-Sixth Annual Continuing Education Conference. Drake Hotel, Chicago, IL. January 20, 1999.
3. Impotence. General Internal Medicine Division Conference, Northwestern Memorial Hospital. Chicago, IL. February 24, 1999.
4. Logical Approach to Erectile Dysfunction. Midwest Clinical Conference. Navy Pier. Chicago, IL. February 26, 1999.
5. Male Sexual Dysfunction. Northwestern Memorial Hospital General Internal Medicine Grand Rounds, Chicago, IL. March 26, 1999.
6. Erectile Dysfunction in Diabetics: American Diabetes Association Support Group. Michael Reese Hospital, Chicago, IL. April 23, 1999.
7. Pharmacologic Management of BPH. 94th Annual Meeting of the American Urological Association. Dallas, Texas. May 4, 1999.
8. Treatment Approaches for an Enlarged Prostate. Prentice Hospital, Chicago, IL. May 17, 1999.
9. New Treatment for Erectile Dysfunction. Northwestern Memorial Hospital, Chicago, IL. June 8, 1999.
10. Treatment Options for Prostate Cancer. Northwestern Memorial Hospital, Chicago, IL. June 24, 1999.
11. Therapeutic Strategies in Impotence. Loyola University Chicago, Division of Medical Continuing Education. Maywood, IL. August 7, 1999.
12. Transurethral Microwave Therapy (TUMT) for BPH. Northwestern Memorial Hospital. Chicago, IL. August 11, 1999.
13. Erectile Dysfunction. The Seventy-Third Annual Meeting of the North Central Section of the AUA Program. Chicago, IL. September 25, 1999.
14. Transurethral Microwave Therapy (TUMT) for BPH. Northwestern Memorial Hospital. Chicago, IL. September 28, 1999.
15. The Molecular Pharmacology of Erection. Grand Rounds. University of Chicago, Chicago, IL. September 29, 1999.
16. Review of Sexual Dysfunction and its Role in SSI. Society for the Study of Impotence 1999. Boston, MA. October 1-3, 1999.
17. Postgraduate Course: Urological Surgery: Impotence – Advances, Evaluation and Therapy. Molecular Pharmacology of Erection. Annual Clinical Congress of the American College of Surgeons. San Francisco, CA. October 10-15, 1999.
18. Medical Management of Benign Prostatic Hypertrophy. Copley-Mercy C.M.E. (Rush-Copley Medical Center/Copley Memorial Hospital and Provena Mercy Center for Health Care Services, Aurora, IL. November 1, 1999.
19. Treatment of Erectile Dysfunction. Thorek Hospital, Grand Rounds, Chicago, IL. February 18, 2000.
20. A Logical Approach to Erectile Dysfunction. Midwest Clinical Conference, Chicago, IL, February 26-28, 2000
21. BPH: New Devices/New Medical Therapies. Clinical Problems in Urology Twenty-Third Annual Seminar.
Allerton Hotel, Chicago, IL. March 31-April 1, 2000.
22. Diagnosis and Management of Prostate Cancer. St. Elizabeth’s Hospital, Chicago, IL. April 11, 2000.
23. Pharmacologic Management of BPH. The Ninety-Fifth Annual Meeting of the American Urological Association, Inc., Atlanta, GA, April 29, 2000.
24. Topical Therapy for the Treatment of Erectile Dysfunction. Annual Meeting of the Society for the Study of Impotence. 2000.
25. Bayer Workshop on Vardenafil – A PDE Inhibitor Under Investigation for the Treatment of Erectile Dysfunction. Hyatt Regency Hotel, Atlanta, GA, April 29, 2000.
26. Advances in the Management of Sexual Dysfunction. Four Seasons Hotel, Chicago, IL. June 26, 2000.
27. Health Policy Issues, Northwestern University Medical School, Chicago, IL, July 27, 2000.
28. Current Issues and Reported Findings from the National Survey on BPH. Rosemont, IL, August 8, 2000.
29. Benign Prostatic Hyperplasia: Long-Term Risks of a Progressive Condition. Chicago, IL, August 29, 2000.
30. Modern Management of the Penile Prosthesis. 2nd Annual ED Strategies Conference. Snowbird Ski and Summer Resort, Cliff Lodge, Snowbird, Utah, September 8-10, 2000.
31. Current Trends in Management of Benign Prostate Hyperplasia (BPH). Embassy Suites, Deerfield, IL, October 24, 2000.
32. Erectile Dysfunction: The Role of Oral and Topical Therapies. Embassy Suites, Deerfield, IL, November 29, 2000.
33. Autonomic Hyperactivity in Symptomatic BPH – From Animal Model to Clinical Assessment. Clinical Society of Genitourinary Surgeons, Northwestern Memorial Hospital, Chicago, IL., November 18, 2000.
34. Prostate Cancer: Management of Treatment Failures. Chicago Urological Society, Chicago, IL, December 6, 2000.
35. Failure of Radiation Therapy for Prostate Cancer. Chicago Urologic Society, Chicago, IL, December 6, 2000.
36. Focus Panel Discussion on Diagnosis of Erectile Dysfunction in the Primary Care Setting. Park Hyatt Hotel, Chicago, IL, January 24, 2001.
37. Logical Approaches to Erectile Dysfunction. Midwest Clinical Conference. Navy Pier, Chicago, IL, February 23, 2001.
38. Northwestern Urology – Honduran Medical Mission. Urological Investigators Forum. Marco Island, FL, March 2-4, 2001.
39. Erectile Dysfunction Post Radical Prostatectomy. Delnor Community Hospital Wellness Center. Geneva, IL, March 21, 2001.
40. Treatment Options for Symptomatic BPH Debate. Pharmacotherapy. Minnesota Urological Society. Bloomington, MN, April 20-21, 2001.
41. New Directions in Treatment of Erectile Dysfunction. Grand Rounds. Highland Park Hospital, Highland Park, IL, April 24, 2001.
42. BPH Therapy: Alpha Blocker Use and Their Effect on Sexual Function. Boehringer Ingelheim Pharmaceuticals, Inc. URO2001 Speaker’s Meeting. Santa Barbara, CA., April 27, 2001.
43. Course Director for Postgraduate Course Minimally Invasive Treatment for BPH. American Urological Association Meeting, Anaheim, CA, June 3, 2001
44. Treatment of BPH with Alpha Blockers: Is There a Difference? American Urological Association. Anaheim, CA, June 3, 2001.
45. Peyronie’s Disease – Current Management. Annual Meeting of the Sexual Medicine Society of North America, Inc., 2001.
46. New Directions in Treatment of Erectile Dysfunction. Medical Grand Rounds. St. Francis Hospital, Evanston, IL. June 15, 2001.
47. Erectile Dysfunction. Prostate Cancer Survivor Lecture Series. Northwestern Memorial Hospital, Chicago, IL. August 21, 2001.
48. Prostate Cancer Awareness. Northwestern Memorial Hospital, Chicago, IL., September 14, 2001.
49. Update of Erectile Dysfunction Treatment Options. Drake Hotel, Chicago, IL., November 1, 2001.
50. Complications and Re-Operations for Penile Prosthesis. Chicago Urological Society, Chicago, IL., November 7, 2001.
51. New Non-Surgical Treatment Options for Erectile Dysfunction. Chicago Urological Society, Chicago, IL., December 5, 2001.
52. Smoking is an Independent Risk Factor for Erectile Dysfunction. Sexual Medicine Society of North America, Inc., Charleston, SC, December 7-9, 2001.
53. The Role of Medical Therapy in the Management of BPH. Medical College of Wisconsin Grand Rounds. Milwaukee, WI, January 4, 2002.
54. The Role of Phytonutrients in the Management of BPH. Medical College of Wisconsin Grand Rounds. Milwaukee, WI, January 4, 2002.
55. Complications of Penile Prosthesis. Postgraduate Course “Annual Advanced Seminar in Urologic Surgery”. University of California San Francisco, San Francisco, CA, January 25-26, 2002.
56. Medical Therapy for Benign Prostatic Hyperplasia (BPH). Postgraduate Course “Annual Advanced Seminar in Urologic Surgery”. University of California San Francisco, San Francisco, CA, January 25-26, 2002.
57. Current Role of Non-TURP Surgical Approaches to BPH. Postgraduate Course “Annual Advanced Seminar in Urologic Surgery”. University of California San Francisco, San Francisco, CA, January 25-26, 2002.
58. Phytonutrients for the Management of BPH. Postgraduate Course “Annual Advanced Seminar in Urologic Surgery”. University of California San Francisco, San Francisco, CA, January 25-26, 2002.
59. Therapeutic Strategies and Collaborative Management Options for Patients with Erectile Dysfunction. The Ritz-Carlton Hotel. Dearborn, MI, March 20, 2002.
60. Innovations in Optimal Therapeutic Intervention for BPH. Grand Rounds, St. Francis Hospital, Evanston, IL, April 5, 2002.
61. Treatment Approaches for an Enlarged Prostate. Healthy Transitions Program 2002. Northwestern Memorial Hospital, Chicago, IL, April 8, 2002.
62. Benign Prostatic Hyperplasia. Grand Rounds, St. Joseph Hospital, Chicago, IL, April 16, 2002.
63. Erectile Dysfunction with Multiple Oral PDE-5 Agents. Salt Lake City, UT, March 29, 2002.
64. TUNA/TUMT Therapies for BPH. Salt Lake City, UT, March 30, 2002.
65. Prevalence and Etiology of Erectile Dysfunction: Relationship to Overall Health and Well-Being. Sponsored by Cogni-Med Town Hall Forum Series, Chicago Hilton Hotel, Chicago, IL, May 9, 2002.
66. Course Director for Postgraduate Course Minimally Invasive Treatment for BPH. American Urological Association Meeting, Orlando, FL. May 25, 2002.
67. Minimally Invasive Therapy for BPH/LUTS-Transurethral Microwave Thermotherapy. American Urological Association Meeting, Orlando, FL. May 25, 2002.
68. The Viagra Experience: Review of Current Data. Viagra ED Private Practice Consultant Meeting sponsored by Pfizer, Inc. Oakbrook Marriott, Oakbrook, IL. August 21, 2002.
69. Medical Knowledge Forums in Urology: A CME Series on the Role of DHT in Prostate Health: An Evolution in Understanding. Sponsored by MED Knowledge Associates. Chicago, IL, September 4, 2002.
70. Prostate CA. Healthy Transitions Program. Northwestern Memorial Hospital, Chicago, IL, September 17, 2002.
71. Intracavernosal Injection Therapy: An Alternative for Salvaging the Sildenafil Failure. The Management of Male Sexual Dysfunction and Other Critical Issues in Men’s Health 2002 Symposium. Sponsored by the College of Physicians and Surgeons, Columbia University. Hotel Inter-Continental Chicago, IL, September 27-28, 2002.
72. Pharmacologic Treatment Options -( Blockers: Terazosin, doxazosin, tamsulosin – Safety and Efficacy and Pharmacologic Treatment Options: Alfuzosin – Safety and Efficacy. BPH: New Treatment Options and Practical Applications. Sofitel Chicago O’Hare, Rosemont, IL, October 19, 2002.
73. PSA as a Marker for BPH. Medical Knowledge Forums in Urology, Phase II Chicago Program. Chicago, IL, November 4, 2002.
74. Medical Therapy of Prostate Symptoms (MTOPS) Trial. Advances in Treatment for BPH in Managed Care: Thought Leader Market Research. Elliott Grand Hyatt Seattle, Seattle, WA. November 9, 2002.
75. Minimally Invasive Therapy. New York University Urology Postgraduate Conference: Surgical, Pharmacological and Technological Advances in Adult and Pediatric Urology: State-of-the-Art. New York, NY. December 6, 2002.
76. Phytotherapy. New York University Urology Postgraduate Conference: Surgical, Pharmacological and Technological Advances in Adult and Pediatric Urology: State-of-the-Art. New York, NY. December 6, 2002.
77. Alfuzosin Clinical Update/Review of Pooled Analysis. Alfuzosin National Advisory Board Meeting. Royal Palms Hotel and Casitas, Phoenix, AZ. December 14-15, 2002.
78. BPH: New Treatment Options and Practical Applications. Four Season Las Colinas, Dallas, TX (Sponsored by the University of Wisconsin Medical School), January 11, 2003.
79. Clinical Update on Treating Erectile Dysfunction: Current Management Issues and Novel Therapeutic Options. Grand Rounds presentation, Northwestern University Feinberg School of Medicine, Chicago, IL , January 23, 2003.
80. New Perspectives in the Management of BPH. Sexual Function and LUTS. Hotel Arts Barcelona, Barcelona, Spain January 31 – February 2, 2003.
81. Smoking and the Risk of Erectile Dysfunction. American College of Preventive Medicine 2003 Conference. Paradise Point Resort Hotel and Spa, San Diego, CA, February 22, 2003.
82. Testosterone Replacement and BPH. Caremark National Pharmacy & Therapeutics Committee Meeting. Four Seasons Hotel, Chicago, IL, February 26, 2003.
83. TUNA. Chicago Urological Association, Inc., Chicago, IL, March 5, 2003.
84. LUTS and BPH, An Emerging Link? Grand Rounds. Our Lady of Resurrection Medical Center, Chicago, IL, March 12, 2003.
85. A Urologist’s Choice of Treatment for BPH. SIU School of Urology, Springfield, IL, March 26, 2003.
86. Midwest Regional Advisory Board. Chicago, IL, March 28-29, 2003.
87. Sexual Dysfunction in Men with Symptoms of BPH. Visiting Professor, Boston University School of Medicine, Department of Urology, Boston, MA, April 2, 2003.
88. Management of Benign Prostatic Hyperplasia. Thorek Hospital and Medical Center, Chicago, IL, April 4, 2003.
89. Erectile Dysfunction Update. Centegra Clinical Symposium on Renal Disease. Holiday Inn Conference Center, Crystal Lake, IL, April 16, 2003.
90. Town Hall Forum Program – Integrating Novel PDE5 Inhibitors in Clinical Practice: Expanding the Therapeutic Window of Opportunity. Marriott Renaissance Center, Detroit, MI April 22, 2003.
91. The Future of Sexual Medicine: Today’s Research, Tomorrow’s Vision. Pathophysiology of Erectile Dysfunction in Patients with LUTS. Knickerbocker Hotel, Chicago, IL, April 26, 2003.
92. Expert Workshop “Novel Options in the Treatment of BPH.” Omni Chicago Hotel, Chicago, IL, April 27, 2003.
93. Course Director for Postgraduate Course Minimally Invasive Treatment for BPH. American Urological Association 98th Annual Meeting, Chicago, IL, April 28, 2003.
94. Microwave Treatment for BPH. American Urological Association 98th Annual Meeting, Chicago, IL, April 28, 2003.
95. Overview of Pivotal Trials for Alfuzosin. Sanofi BPH Investigators Meeting. Drake Hotel, Chicago, IL, April 29, 2003.
96. Clinical Evaluation of Benign Prostatic Hyperplasia. An Opinion Leader Roundtable and Supplement. The Waldorf-Astoria, New York, May 27-28, 2003.
97. Erectile Dysfunction Update. Grand Rounds. University of Texas Houston Medical School, Division of Urology, Houston, TX, June 12, 2003.
98. BPH Progression in 2003. University of Texas Houston Medical School, Division of Urology, Houston TX, June 12, 2003.
99. Integration of Novel PDE5 Inhibitors for Erectile Dysfunction; Expanded Opportunities for Successful Patient Outcomes. CIEF Town Hall Forum Program. Hyatt Regency St. Louis at Union Station, St. Louis, MO, September 23, 2003.
100. Sexual Function and Alpha-Blockers. BPH & Beyond Educational Council Summit. Waldorf-Astoria, New York, NY, September 30, 2003.
101. Pri-Med Update Meeting. Clinical Update for BPH/Contemporary Options for the Management of BPH, Atlanta, GA, October 8, 2003.
102. BPH – Implications for Population Health Management. Disease Management Association of America, Chicago Hyatt, Chicago, IL, October 14, 2003.
103. Management of Erectile Dysfunction. Northwestern Memorial Hospital, Chicago, IL, October 14, 2003.
104. Review of BPH and the Role of Uroxatral, Including a Review of Pertinent Clinical Data. Uroxatral NP/PA Advisory Board, Drake Hotel, Chicago, IL, October 18, 2003.
105. Sexual Function and Alpha Blockers. BPH and Beyond Key Opinion Leader Scientific Session. The Waldorf-Astoria, New York, NY, October 28-29, 2003.
106. Urologic Complication of Diabetes. Session III: Female and Male Sexual Function Complications. Introduction on Basic Research. NIH Lister Hill Auditorium, NIH Campus, Bethesda, MD, December 3-4, 2003.
107. Key Opinion Leader Meeting – TUNA. Millennium UN Plaza Hotel, New York, NY, December 5, 2003.
108. Consortium for Improvement of Erectile Function Distinguished Faculty Meeting. InterContinental The Barclay, New York, NY, December 5-7, 2003.
109. Advances in ED. Visiting Professor, University of Minnesota, Department of Urology, Minneapolis, MN, January 9, 2004.
110. Advances in Medical Treatment for BPH. Visiting Professor, University of Minnesota, Minneapolis, MN, January 9, 2004.
111. Minimally Invasive Treatment for BPH. Visiting Professor, University of Minnesota, Minneapolis, MN, January 9, 2004.
112. Molecular Mechanisms of Post Radical Prostatectomy Erectile Dysfunction. Visiting Professor, University of Washington, Department of Urology, Grand Rounds, Seattle, WA, January 23-24, 2004.
113. PDE5 Inhibitor Drugs. Chicago Urological Society, Chicago, IL, February 4, 2004.
114. Major Findings of the Landmark MTOPS. International Cardura Faculty Meeting, Zurich, Switzerland, February 7-8, 2004.
115. Medical Management of BPH. Grand Rounds, Northwestern Memorial Hospital, Chicago, IL., March 4, 2004.
116. Advances in the Management of Erectile Dysfunction. Clinical Issues and Challenging Cases. CIEF Thought Leader Seminar. Omni River Place, Detroit, MI, April 20, 2004.
117. Ischemia Affects the Structure of the Prostate. International BPH and Sexual Dysfunction Workshop. Four Seasons Hotel, New York, NY, April 30-May 1, 2004.
118. Minimally Invasive Treatment for BPH. American Urological Association Annual Meeting, San Francisco, CA, May 8, 2004.
119. Causation or Coincidence? Sexual Medicine Society of North America Annual Scientific Meeting. Argent Hotel, San Francisco, CA, May 9, 2004.
120. Latest Data on the Treatment of BPH and Sexual Function Symposium at the American Urological Association Meeting, Western St. Francis, San Francisco, CA, May 11, 2004.
121. Advances in the Management of Erectile Dysfunction. Clinical Issues and Challenging Cases. CIEF Thought Leader Seminar. Westin Galleria, Dallas, TX, May 28, 2004.
122. Sexual Dysfunction, LUTS and Alpha Blockers. BPH and Beyond Key Opinion Leader Scientific Session. The Plaza Hotel, New York, June 11-12, 2004.
123. Geriatric Urology and Andropause. Northwestern Memorial Hospital, Pritzker Auditorium, Chicago, IL, July 1, 2004.
124. ED Cases: Troubleshooting the IPP. Northwestern Memorial Hospital, Pritzker Auditorium, Chicago, IL, July 1, 2004.
125. Clinical Correlation between ED and Lower Urinary Tract Symptoms. Doctor on Call, Vol. 3, No. 9 Audio Discussion. The Madison Hotel, Morristown, NJ, August 16, 2004.
126. Erectile Dysfunction. Health Transitions and Prostate Cancer Group Program. Northwestern Memorial Hospital, Pritzker Auditorium, Chicago, IL, September 24, 2004.
127. BPH – Freedom from Lower Urinary Tract Symptoms (LUTS). Perspectives in Men’s Health: Your Male Patient: State-of-the-Art Clinical Management. The Houstonian Hotel, Houston, TX, October 1, 2004.
128. New Treatments for LUTS Secondary to BPH. Rationale Evidence and Efficacy. Medical College of Georgia Urology Grand Rounds, Augusta, GA, October 7, 2004.
129. Examining the Evidence on the Link BPH/Sexual Dysfunction. 11th World Congress of the International Society for Sexual and Impotence Research. New Frontiers in Sexual Medicine Roundtable, Sheraton Buenos Aires Hotel and Convention Center, Buenos Aires, Argentina, October 17-19, 2004.
130. Epidemiology and Basic Science. Sexual Medicine Society of North America Research Meeting. Royal Sonesta Hotel, New Orleans, LA, January 13, 2005.
131. BPH and LUTS. Sexual Medicine Society of North America Research Meeting. Royal Sonesta Hotel, New Orleans, LA, January 15, 2005.
132. State-of-the-Art Lecture: LUTS and ED. Sexual Medicine Society of North America Research Meeting. Royal Sonesta Hotel, New Orleans, LA, January 16, 2005.
133. Overactive Bladder: Current Concepts of Management. Contemporary Issues in Adult Urology. Mayo Clinic Continuing Medical Education Program Postgraduate Course. Hapuna Beach, Hawaii, February 16, 2005.
134. Minimally Invasive Procedures in the Management of BPH. Contemporary Issues in Adult Urology. Mayo Clinic Continuing Medical Education Program Postgraduate Course. Hapuna Beach, Hawaii, February 18, 2005.
135. TUNA: Current Perspectives. Contemporary Issues in Adult Urology. Mayo Clinic Continuing Medical Education Program Postgraduate Course. Hapuna Beach, Hawaii, February 18, 2005.
136. Molecular Mechanisms of Post-Radical Prostatectomy Erectile Dysfunction. Transamerican Urologic Researchers Meeting, Rancho Bernardo Inn, San Diego, CA, March 10-11, 2005.
137. The Long Term Effects of Doxazosin, Finasteride, and the Combination on Sexual Function in Men Participating in the MTOPS Study. Transamerican Urologic Researchers Meeting, Rancho Bernardo Inn, San Diego, CA, March 10-11, 2005.
138. LUTS and ED: A Mechanistic Explanation. The Society for Urodynamics and Female Urology Program, Henry B. Gonzalez Convention Center, San Antonio, TX, May 21, 2005.
139. Injection Therapy for Peyronie’s Disease – Effective. Sexual Medicine Society of North America Meeting, San Antonio Marriott Riverwalk, San Antonio, TX, May 22, 2005.
140. Course Director, Postgraduate Course #54, Office-Based Minimally Invasive Treatments for BPH. Marriott Rivercenter, San Antonio, TX, May 23, 2005.
141. The 3 P’s of EP: Prevalence, Progression and Prediction. Diagnosis and Medical Management of Enlarged Prostate in the Primary Care Setting. Ritz Carlton Dearborn, Dearborn, MI, June 4, 2005.
142. Consensus Based Recommendations in Reducing Treatment Gaps in Primary Care Management of EP. Ritz Carlton Dearborn, Dearborn, MI, June 4, 2005.
143. The 3 P’s of EP: Prevalence, Progression and Prediction. Diagnosis and Medical Management of Enlarged Prostate in the Primary Care Setting. Hyatt Regency Chicago, Chicago, IL, June 25, 2005.
144. LUTS and Sexual Dysfunction: Epidemiology and Pathophysiology. BPH Experts Forum UroXChange International Meeting. Monte Carlo, October 14-16, 2005.
145. Rho Kinase Protein Abundance is Increased with Diabetic Erectile Dysfunction. 26th Annual Jackson Hole Conference, Jackson, WY, January 29, 2006.
146. Metabolic Syndrome and LUTS Secondary to BPH. 26th Annual Jackson Hole Conference, Jackson, WY, January 31, 2006.
147. Neural Regulation of Sonic Hedgehog in the Penis. 26th Annual Jackson Hole Conference, Jackson, WY, January 31, 2006.
148. Molecular Mechanism of Post-radical Prostatectomy. 26th Annual Jackson Hole Conference, Jackson, WY, February 1, 2006.
149. Clinical Outcomes of a Modern Series of Open Prostatectomy for Large Benign Prostates. 26th Annual Jackson Hole Conference, Jackson, WY, February 2, 2006.
150. The Efficacy and Safety of Tadalafil Administered Once a Day for Lower Urinary Tract Symptoms (LUTS) in Men with Benign Prostatic Hyperplasia (BPH). Annual Congress of European Urology Association (EAU), Paris, France, April 5-8, 2006.
151. Erectile Dysfunction Following Prostate Cancer Surgery: Molecular Mechanisms of ED. American Society of Andrology Postgraduate Course. Issues in Male Sexual Health: From Benchwork to Bedside. 31st Annual Conference, Hyatt Regency Chicago on the Riverwalk, Chicago, IL, April 8, 2006.
152. Sexual Dysfunction and LUTS: Is It causal or a Causal Association? American Society of Andrology Postgraduate Course. Issues in Male sexual Health: From Benchwork to Bedside. 31st Annual Conference, Hyatt Regency Chicago on the Riverwalk, Chicago, IL, April 8, 2006.
153. LUTS, ED and PDE Inhibitors: Historical and Novel Concepts. CME Satellite Symposium “Inhibitors and Androgens in Prostate Disease: Current and Future Strategies. Georgia World Congress Center, Atlanta, GA, May 19, 2006.
154. BPH/LUTS and ED: Is it More than Just an Association? Endocrine Forum 2006, Update on BPH/LUTS. Georgia World Congress Center, Atlanta, GA, May 22, 2006.
155. PDE5 – Is and LUTS. The Therapist and the Therapy Updates and Emerging Trends. Ritz Carlton Buckhead, Atlanta, GA, May 22, 2006.
156. Course Director for Postgraduate Course BPH: Office Based Minimally Invasive Treatments. American Urological Association Meeting, Atlanta, GA, May 23, 2006.
157. Sexual Dysfunction. Healthy Transition Program. Northwestern Memorial Hospital, Chicago, IL, June 22, 2006.
158. BPH: Therapeutic Perspective. Caremark National Pharmacy and Therapeutics Meeting. Four Seasons Hotel, Chicago, IL, August 23, 2006.
159. Course Director for the North Central Section 80th Annual Meeting of the American Urological Association: Update on BPH: What’s a Urologist to Do? Hotel del Coronado, San Diego, CA, September 11, 2006.
160. HoLAP (100 Holmium Ablation for BPH) – Clinical Outcomes. North Central Section 80th Annual Meeting of the American Urological Association, Hotel del Coronado, San Diego, CA, September 11, 2006.
161. Management of LUTS/BPH with Open Prostatectmy – Results of a Contemporary Series. North Central Section 80th Annual Meeting of the American Urological Association, Hotel del Coronado, San Diego, CA, September 16, 2006.
162. Male Sexuality: A Focus on Erectile Dysfunction. Northwestern Memorial Hospital, Chicago, IL, September 28, 2006.
163. Transurethral Needle Ablation (TUNA). Chicago Urological Society, Chicago, IL, November 1, 2006.
164. HBP, LUTS and DE: Fiction or Reality. Quebec Urological Association Annual Meeting. Chateau Frontenac, Quebec City, Canada, November 3, 2006.
165. Ejaculatory Dysfunction in the Aging Male. Quebec Urological Association Annual Meeting. Chateau Frontenac, Quebec City, Canada, November 4, 2006.
166. The Relationship between LUTS/BPH and Erectile Dysfunction. Society for Basic Urologic Research 16th Annual Meeting, Phoenix, AZ, November 17, 2006.
167. Molecular Mechanisms of Erectile Dysfunction. Northwestern University Feinberg School of Medicine, Chicago, IL, March 22, 2007.
168. BPH and Overall Prostate Health. 26th Annual Big Sky Pulmonary and Critical Care Conference, Big Sky, Montana, March 29-April 1, 2007.
169. Minimally Invasive Interventions/Surgery. Urology Congress, San Francisco, CA, April 4-7, 2007.
170. Erectile Dysfunction: Links to Heart Health. Northwestern Memorial Hospital, Chicago, IL, April 11, 2007.
171. Overlapping Issues of Male LUTS and Sexual Dysfunction. Curatio CME AUA Symposium: Novel Insights into the Development and Treatment of Male LUTS. Anaheim, CA, May 18, 2007.
172. LUTS, BPH and Erectile Dysfunction. Seventh Congress of Turkish Society of Andrology. Ankara, Turkey, June 7-9, 2007.
173. BPH Expert Panel Meeting. Paris, France, September 2, 2007.
174. State-of-the-Art Lecture. Current Medical Management of LUTS/BPH/Male Voiding Dysfunction. 2007 Annual Meeting of the Northeastern Section of the AUA, Rochester, NY, September 6, 2007.
175. Improvement with Sildenafil in Men with moderate and Severe Lower Urinary Tract Symptoms. North Central Section AUA Meeting, Hollywood, FL, October 31, 2007.
176. Penis, Prostate and PDE5. Presented at the 10th European Society for Sexual Medicine Congress, R-1 Round Table, Lisbon, November 27, 2007.
177. Chair and Moderator. Sexual Medicine Society of North America, Westin River North, Chicago, IL, December 6-9, 2007.
178. Body Mass Index Affects the Response to Sildenafil in Men with Moderate and Severe Lower Urinary Tract Symptoms. Sexual Medicine Society of North America, Westin River, North, Chicago, IL, December 6-9, 2007.
179. BPH Treatment Guidelines – Evolution of a Disease. Chicago Urological Society, 81 E. Van Buren, Chicago, IL, February 6, 2008.
180. Update on Traditional and Non-Traditional Medical Treatments for Male Sexual Dysfunction. Sexual Disorders: Latest Research Effective Treatment. Society for Sex Therapy and Research 33rd Annual Meeting. Inter Continental Chicago Hotel, Chicago, IL, March 15, 2008.
181. American Urological Association (AUA) Lecture. BPH, LUTS and Erectile Dysfunction. 23rd Annual European Association of Urology Congress. Milano Convention Centre, Milan, Italy, March 28, 2008.
182. BPH, ED, Physiology of Erection and Priapism. Specialty Review in Urology (Sponsored by the University of Chicago, CME Course). Wyndham Drake Oak Brook, IL, April 6, 2008.
183. Office Procedures. Ohio Urological Society. Kalahari Resort and Convention Center, Sandusky, OH, April 19, 2008.
184. Prostate, Penis and PDE-5: Overlapping Issues of Male LUTS and Erectile Dysfunction. Sommer Memorial Lectures/Oregon Health and Science University School of Medicine Alumni Scientific Meeting, Portland, OR, May 8, 2008.
185. Metabolic Syndrome and LUTS Secondary to BPH. Sommer Memorial Lectures/Oregon Health and Science University School of Medicine Alumni Scientific Meeting, Portland, OR, May 8, 2008.
186. Molecular Mechanisms of Post-Radical Prostatectomy Erectile Dysfunction. Sommer Memorial Lectures/Oregon Health and Science University School of Medicine Alumni Scientific Meeting, Portland, OR, May 8, 2008.
187. Case Presentations in Andrology. Turkish Society of Andrology Congress, Istanbul, Turkey, June 6, 2008.
188. Medical Treatment of LUTS-Case Presentations. Turkish Society of Andrology Congress, Istanbul, Turkey, June 6, 2008.
189. PDE5 Inhibitors Effective in LUTS. Turkish Society of Andrology Congress, Istanbul, Turkey, June 7, 2008.
190. Factors Effecting Progression in BPH. Turkish Society of Andrology Congress, Istanbul, Turkey, June 7, 2008.
191. Prostate Cancer and Benign Prostatic Hyperplasia -Treatment Options and the Future of Treatment. Men’s Health: Prioritizing Prevention, Early Detection and Treatment. Congressional Staff Brief on Men’s Health, Longsworth House Office Building, Room 1116, Washington, DC, September 24, 2008.
192. Metabolic Syndrome and LUTS Secondary to BPH. Visiting Professor, the University of Toledo Medical Center, Toledo, OH, October 3, 2008.
193. What Has Basic Science Informed Us about the Etiology of BPH and LUTS? Workshop on Modifiable Risk Factors for BPH and LUTS. Double Tree Hotel and Executive Meeting Center, Bethesda, MD, October 13-14, 2008. Meeting sponsored by DKUHD, NIDDK and NIH.
194. State-of-the-Art Lecture: An Update on LUTS and ED. Sexual Medicine Society of North America. Westin Harbour Castle Hotel, Toronto, Canada, October 18, 2008.
195. Managing LUTS Successfully in the Aging Male Bladder: OAB vs. BPH vs. Surgery? Chicago Urological Society, The Chicago Club, Chicago, IL, December 3, 2008.
196. Current Treatment of Erectile Dysfunction. Year in Internal Medicine Conference. Northwestern Memorial Hospital, Chicago, IL, January 23, 2009.
197. 2009 IUA Annual Meeting, Indianapolis, IN, February 6-7, 2009.
198. Erectile Health and Heart Disease. The Health Learning Centers for Wellness Wednesdays for Men. Northwestern Memorial Hospital, Chicago, IL, February 18, 2009.
199. Erectile Dysfunction. AUA Educational Program “Primary Care Update in Urology”, Hyatt McCormick, Chicago, IL, April 25, 2009.
200. Male Pelvic Health and BPH: What Urologists’ Need to Know. American Urological Association Meeting, Chicago, IL, April 26, 2009.
201. BPH/LUTS: New Concepts in Diagnosis and Management. Men’s Health: Opening a New Frontier. Beth Israel Deaconess Medical Center, Division of Urology. Boston, MA, May 16, 2009.
202. Erectile Dysfunction: What’s Next? Men’s Health: Opening a New Frontier. Beth Israel Deaconess Medical Center, Division of Urology. Boston, MA, May 16, 2009.
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.